[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 215
1. Malhotra AK, Bansal A, Mridha AR, Khaitan BK, Verma KK: Superficial basal cell carcinoma on face treated with 5% imiquimod cream. Indian J Dermatol Venereol Leprol; 2006 Sep-Oct;72(5):373-5
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Superficial basal cell carcinoma on face treated with 5% imiquimod cream.
  • We report our experience of treating a large superficial spreading basal cell carcinoma with 5% imiquimod cream.
  • Biopsy from the lesion showed features of basal cell carcinoma.
  • [MeSH-major] Aminoquinolines / administration & dosage. Carcinoma, Basal Cell / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Aged. Face / pathology. Humans. Male. Ointments

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17050935.001).
  • [ISSN] 0973-3922
  • [Journal-full-title] Indian journal of dermatology, venereology and leprology
  • [ISO-abbreviation] Indian J Dermatol Venereol Leprol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Ointments; 99011-02-6 / imiquimod
  •  go-up   go-down


2. Jadotte YT, Sarkissian NA, Kadire H, Lambert WC: CASE REPORT Superficial Spreading Basal Cell Carcinoma of the Face: A Surgical Challenge. Eplasty; 2010;10:e46

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CASE REPORT Superficial Spreading Basal Cell Carcinoma of the Face: A Surgical Challenge.
  • OBJECTIVE: We present the case of a white man with a facial nodule suspicious for basal cell carcinoma.
  • METHODS: Biopsy revealed clusters of basaloid tumor cells with peripheral palisading, consistent with a superficial spreading variant of basal cell carcinoma.
  • However, since it was a superficial spreading basal cell carcinoma, this was followed by topical imiquimod treatment.
  • CONCLUSION: Topical chemotherapy with imiquimod or 5-fluorouracil may be valuable alternatives or adjuncts, given the increased likelihood of recurrence after surgical excision of superficial spreading basal cell carcinoma.
  • Mohs surgery is of limited value in the management of superficial spreading basal cell carcinoma because it characteristically shows areas of uninvolved skin between tumor nests.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Dermatol. 2003 Feb;148(2):195-202 [12588368.001]
  • [Cites] J Invest Dermatol. 2003 Jun;120(6):1087-93 [12787139.001]
  • [Cites] Br J Dermatol. 2004 Jul;151(1):141-7 [15270883.001]
  • [Cites] J Am Acad Dermatol. 2005 Mar;52(3 Pt 1):468-73 [15761425.001]
  • [Cites] J Am Acad Dermatol. 2005 Sep;53(3):445-51 [16112351.001]
  • [Cites] Dermatol Surg. 2009 Sep;35(9):1349-54 [19500127.001]
  • [Cites] Br J Nurs. 2009 Jan 8-21;18(1):8-16 [19127226.001]
  • [Cites] J Chin Med Assoc. 2006 Aug;69(8):364-71 [16970272.001]
  • [Cites] Cochrane Database Syst Rev. 2007;(1):CD003412 [17253489.001]
  • [Cites] Drugs. 2007;67(6):915-34 [17428108.001]
  • [Cites] Acta Clin Croat. 2008 Mar;47(1):25-30 [18714644.001]
  • [Cites] Int J Dermatol. 2008 Oct;47(10):1015-8 [18986346.001]
  • [Cites] Br J Dermatol. 2006 Aug;155(2):401-7 [16882181.001]
  • (PMID = 20596236.001).
  • [ISSN] 1937-5719
  • [Journal-full-title] Eplasty
  • [ISO-abbreviation] Eplasty
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2890390
  •  go-up   go-down


3. Jain VK, Verma SS, Verma AS, Munjal KR, Swarnakar B: Basal cell carcinoma over chest wall (sternum) treated with dufourmentel flap: report of a case with review of literature. J Cutan Aesthet Surg; 2010 May;3(2):115-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma over chest wall (sternum) treated with dufourmentel flap: report of a case with review of literature.
  • Basal cell carcinoma (BCC) is the most common malignancy of the skin, accounting for approximately 70-80% of all cutaneous cancers.
  • The commonest site of basal cell carcinoma is the face; 80% arise above a line from the corner of the mouth to the ear lobe.
  • The lifetime ultraviolet radiation damage is the most important factor in its pathogenesis, and the vast majority is observed on sun-exposed skin.
  • A clinical diagnosis of BCC was made and patient was subjected to excision biopsy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21031073.001).
  • [ISSN] 0974-5157
  • [Journal-full-title] Journal of cutaneous and aesthetic surgery
  • [ISO-abbreviation] J Cutan Aesthet Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2956953
  • [Keywords] NOTNLM ; Basal cell carcinoma / dufourmentel flap / rhomboid transposition flap / sternum
  •  go-up   go-down


Advertisement
4. Essers BA, Dirksen CD, Nieman FH, Smeets NW, Krekels GA, Prins MH, Neumann HA: Cost-effectiveness of Mohs Micrographic Surgery vs Surgical Excision for Basal Cell Carcinoma of the Face. Arch Dermatol; 2006 Feb;142(2):187-94
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cost-effectiveness of Mohs Micrographic Surgery vs Surgical Excision for Basal Cell Carcinoma of the Face.
  • OBJECTIVE: To assess the cost-effectiveness of Mohs micrographic surgery (MMS) compared with the surgical excision for both primary and recurrent basal cell carcinoma (BCC).
  • [MeSH-major] Carcinoma, Basal Cell / economics. Facial Neoplasms / economics. Mohs Surgery / economics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Arch Dermatol. 2006 Feb;142(2):231-2 [16490852.001]
  • [CommentIn] Arch Dermatol. 2006 Sep;142(9):1235; author reply 1235-6 [16983019.001]
  • (PMID = 16490846.001).
  • [ISSN] 0003-987X
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


5. Archontaki M, Stavrianos SD, Korkolis DP, Arnogiannaki N, Vassiliadis V, Liapakis IE, Christ H, Rapidis AD, Kokkalis G: Giant Basal cell carcinoma: clinicopathological analysis of 51 cases and review of the literature. Anticancer Res; 2009 Jul;29(7):2655-63
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant Basal cell carcinoma: clinicopathological analysis of 51 cases and review of the literature.
  • BACKGROUND: Giant basal cell carcinoma (GBCC) is an aggressive malignant neoplasm.
  • It develops as long-standing dermal tumor with mean disease duration of 14.5 years and is most commonly located on the back, followed by the face and upper extremity.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Skin Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19596942.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Greece
  • [Number-of-references] 54
  •  go-up   go-down


6. Olschewski T, Bajor K, Lang B, Lang E, Seegenschmiedt MH: [Radiotherapy of basal cell carcinoma of the face and head: Importance of low dose per fraction on long-term outcome]. J Dtsch Dermatol Ges; 2006 Feb;4(2):124-30
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Radiotherapy of basal cell carcinoma of the face and head: Importance of low dose per fraction on long-term outcome].
  • BACKGROUND: Radiotherapy plays an important role in the treatment of basal cell carcinoma of the face and head and achieves cure rates of 92-96 %.
  • PATIENTS AND METHODS: 85 patients with 104 tumors underwent radiotherapy for basal cell carcinoma of the face and head.
  • This fractionation can be recommended as a standardized radiotherapy treatment for basal cell carcinoma of the face and head.
  • [MeSH-major] Carcinoma, Basal Cell / radiotherapy. Facial Neoplasms / radiotherapy. Head and Neck Neoplasms / radiotherapy. Skin Neoplasms / radiotherapy

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Dtsch Dermatol Ges. 2006 Feb;4(2):101-2 [16503936.001]
  • (PMID = 16503939.001).
  • [ISSN] 1610-0379
  • [Journal-full-title] Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
  • [ISO-abbreviation] J Dtsch Dermatol Ges
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 75
  •  go-up   go-down


7. Custódio G, Locks LH, Coan MF, Gonçalves CO, Trevisol DJ, Trevisol FS: Epidemiology of basal cell carcinomas in Tubarão, Santa Catarina (SC), Brazil between 1999 and 2008. An Bras Dermatol; 2010 Nov-Dec;85(6):819-26
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidemiology of basal cell carcinomas in Tubarão, Santa Catarina (SC), Brazil between 1999 and 2008.
  • BACKGROUND: Skin cancer is the most frequent type of neoplasm in Brazil.
  • There are no data on the incidence of basal cell carcinoma in the Southern region of Santa Catarina.
  • OBJECTIVE: To establish epidemiological data on basal cell carcinoma in Tubarão, Santa Catarina, between 1999 and 2008.
  • METHODS: A cross-sectional study was conducted in which anatomopathological reports of basal cell carcinoma from the laboratories of Tubarão, Santa Catarina, were analyzed.
  • We considered the following variables: year of diagnosis, age, gender, city of origin, tumor site, histological subtype, lesion diameter, margin involvement, and relapse.
  • RESULTS: Reports of 3,253 subjects most frequently between the ages of 61 and 80 years diagnosed with basal cell carcinoma were obtained.
  • The incidence of basal cell carcinoma was 164.5 cases per 100,000 inhabitants in 1999 and 295.2 per 100,000 in 2008, showing an increase of 80%.
  • There was an association between males and basal cell carcinoma of the torso and ear, and between females and basal cell carcinoma of the nose.
  • Based on multivariate analysis, lesions of 2 cm in diameter were 5.5 times more likely to present margin involvement, and basal cell carcinoma of the face was 1.8 times more likely to occur (p <0.0001).
  • [MeSH-major] Carcinoma, Basal Cell / epidemiology. Skin Neoplasms / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21308305.001).
  • [ISSN] 1806-4841
  • [Journal-full-title] Anais brasileiros de dermatologia
  • [ISO-abbreviation] An Bras Dermatol
  • [Language] eng; por
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


8. Erba P, Farhadi J, Wettstein R, Arnold A, Harr T, Pierer G: Morphoeic basal cell carcinoma of the face. Scand J Plast Reconstr Surg Hand Surg; 2007;41(4):184-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Morphoeic basal cell carcinoma of the face.
  • The morphoeic (or sclerosing) basal cell carcinoma (mBCC) is the most aggressive subtype, as it spreads into the dermis beyond the clinically visible or palpable borders, making complete excision difficult.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17701732.001).
  • [ISSN] 0284-4311
  • [Journal-full-title] Scandinavian journal of plastic and reconstructive surgery and hand surgery
  • [ISO-abbreviation] Scand J Plast Reconstr Surg Hand Surg
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


9. Erba P, Wettstein R, Rieger UM, Beltraminelli H, Pierer G, Kalbermatten DF: Reducing the learning curve for the treatment of morphoeic (sclerosing) basal cell carcinoma of the face. Scand J Plast Reconstr Surg Hand Surg; 2008;42(3):122-6
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reducing the learning curve for the treatment of morphoeic (sclerosing) basal cell carcinoma of the face.
  • The treatment of morphoeic (or sclerosing) basal cell carcinoma (mBCC) of the face is associated with high rates of incomplete excision and recurrence.
  • We did a prospective, randomised study of 40 consecutive patients with mBCC of the face.
  • The data from a former retrospective study of all excisions of mBCC of the face during a five-year period at the hospital served as control.
  • High magnification and good lighting were useful in learning how to recognise skin changes associated with mBCC of the face and achieving a low rate of incomplete excisions.

  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18470787.001).
  • [ISSN] 0284-4311
  • [Journal-full-title] Scandinavian journal of plastic and reconstructive surgery and hand surgery
  • [ISO-abbreviation] Scand J Plast Reconstr Surg Hand Surg
  • [Language] ENG
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  •  go-up   go-down


10. Micali M, Nasca MR, Musumeci ML: Treatment of an extensive superficial basal cell carcinoma of the face with imiquimod 5% cream. Int J Tissue React; 2005;27(3):111-4
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of an extensive superficial basal cell carcinoma of the face with imiquimod 5% cream.
  • The efficacy and safety of imiquimod, an immune-response modifier approved for the treatment of anogenital warts that has antiviral and antitumor activity, in the management of an extensive superficial basal cell carcinoma (sBCC) of the face as an alternative to surgical treatment was evaluated in a 75-year-old male with a 4-year history of a progressively enlarging lesion located on the right temporal region.
  • Histopathological confirmation of clinical diagnosis and of tumor clearance were performed before starting treatment and at the end of treatment, respectively.
  • Our findings confirm current reports from the literature showing imiquimod 5% cream to be an effective treatment for sBCC that is especially valuable in avoiding disfigurement in cases of single large lesions located on the face or in those patients who may not be surgical candidates.
  • [MeSH-major] Adjuvants, Immunologic / therapeutic use. Aminoquinolines / therapeutic use. Carcinoma, Basal Cell / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Administration, Topical. Aged. Drug Administration Schedule. Face. Follow-Up Studies. Humans. Male. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16372477.001).
  • [ISSN] 0250-0868
  • [Journal-full-title] International journal of tissue reactions
  • [ISO-abbreviation] Int J Tissue React
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Aminoquinolines; 99011-02-6 / imiquimod
  •  go-up   go-down


11. Mosterd K, Krekels GA, Nieman FH, Ostertag JU, Essers BA, Dirksen CD, Steijlen PM, Vermeulen A, Neumann H, Kelleners-Smeets NW: Surgical excision versus Mohs' micrographic surgery for primary and recurrent basal-cell carcinoma of the face: a prospective randomised controlled trial with 5-years' follow-up. Lancet Oncol; 2008 Dec;9(12):1149-56
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical excision versus Mohs' micrographic surgery for primary and recurrent basal-cell carcinoma of the face: a prospective randomised controlled trial with 5-years' follow-up.
  • BACKGROUND: Basal-cell carcinoma (BCC) is the most common form of skin cancer and its incidence is still rising worldwide.
  • The primary outcome was recurrence of carcinoma, diagnosed clinically by visual inspection with histological confirmation.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Facial Neoplasms / surgery. Health Care Costs. Mohs Surgery / economics. Neoplasm Recurrence, Local / surgery. Skin Neoplasms / surgery


12. Kozyreva ON, Konnikov N: The incidence of non-melanoma skin cancer after a single field treatment with aminolevulinic acid and blue light photodynamic therapy. J Clin Oncol; 2009 May 20;27(15_suppl):e14646

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The incidence of non-melanoma skin cancer after a single field treatment with aminolevulinic acid and blue light photodynamic therapy.
  • : e14646 Background: Non-melanoma skin cancer (NMSC) is the most common form of human cancer.
  • Study pts received a single application of 20 % ALA to the face or scalp following by exposure to blue light at 10 J/cm2.
  • RESULTS: 43 Caucasian males (range 59- 87 yrs), 37 (87%) had history of NMSC on the face or scalp, 32 (78%) had basal cell carcinoma (BCC), 11 (22%) squamous cell carcinoma (SCC), 100% of patients had multiple (>4) AKs prior to treatment and 23 (75% ) had moderate to severe DH determined by Griffiths scale.
  • No such differences were observed between the frequency of SCC before and after ALA-PDT (P=0.6230) Conclusions: A single ALA-PDT treatment to the face or scalp in high risk patients significantly reduces the incidence of BCC, the incidence of SCC was not reduced.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964235.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Shah SA, Obaidullah, Fahimullah: An assessment of incomplete facial Basal cell carcinoma excision. J Coll Physicians Surg Pak; 2005 Mar;15(3):149-51
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An assessment of incomplete facial Basal cell carcinoma excision.
  • OBJECTIVE: To determine the rate and cause(s) of incomplete excision of basal cell carcinoma, occurring on face.
  • PATIENTS AND METHODS: Patients with basal cell carcinoma of the face reporting to the OPD were included in the study and were booked for surgery.
  • After excision, all tumors specimens were marked at 12 o'clock and sent to laboratory for histopathology to confirm the diagnosis and to know the completeness/incompleteness of tumor excision.
  • CONCLUSION: Chances of incomplete tumor excision are more on the mid face region.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Facial Neoplasms / surgery. Neoplasm Invasiveness / pathology. Neoplasm Recurrence, Local / epidemiology. Skin Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15808092.001).
  • [ISSN] 1022-386X
  • [Journal-full-title] Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  • [ISO-abbreviation] J Coll Physicians Surg Pak
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Pakistan
  •  go-up   go-down


14. Sohn MH, Lim ST, Jeong HJ, Kim DW, Jang KY, Yim CY: Intraosseous lipoma in the femoral shaft mimicking a bone metastasis on bone scintigraphy. Clin Nucl Med; 2009 Oct;34(10):693-5
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Bone scintigraphy demonstrated a focal area of uptake in the right femoral shaft mimicking a bone metastasis in a 52-year-old man with basal cell carcinoma of the face.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19893404.001).
  • [ISSN] 1536-0229
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


15. Rodríguez-Domínguez FJ, Hernández-Gil J, Segarra Fenoll JD, Hernández-Gil A: [Facial mutilant basosquamous carcinoma]. An Otorrinolaringol Ibero Am; 2007;34(6):549-55
MedlinePlus Health Information. consumer health - Palliative Care.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Facial mutilant basosquamous carcinoma].
  • [Transliterated title] Carcinoma basoescamoso mutilante en región facial.
  • Basosquamous carcinoma is a rare epithelial malignant neoplasm with clinical and biological features of both basal and squamous cell carcinoma.
  • This neoplasm has been characterized for years as a variant of basal cell carcinoma, although now it is widely accepted as a clinical entity.
  • The most important features of basosquamous carcinoma are its great local aggressiveness, high frequency of recurrences and its metastatic potential.
  • [MeSH-major] Carcinoma, Basosquamous / pathology. Head and Neck Neoplasms / pathology. Palliative Care / methods
  • [MeSH-minor] Anti-Bacterial Agents / therapeutic use. Face. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18293774.001).
  • [ISSN] 0303-8874
  • [Journal-full-title] Anales otorrinolaringológicos ibero-americanos
  • [ISO-abbreviation] An Otorrinolaringol Ibero Am
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents
  •  go-up   go-down


16. Rio E, Bardet E, Ferron C, Peuvrel P, Supiot S, Campion L, Beauvillain De Montreuil C, Mahe MA, Dreno B: [Interstitial brachytherapy of peri-orificial skin carcinomas on the face]. Cancer Radiother; 2006 May;10(3):101-6
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Interstitial brachytherapy of peri-orificial skin carcinomas on the face].
  • [Transliterated title] Curiethérapie interstitielle des cancers cutanés des zones périorificielles de la face.
  • Purpose. - To analyse outcomes after interstitial brachytherapy of facial periorificial skin carcinomas.
  • - We performed a retrospective analysis of 97 skin carcinomas (88 basal cell carcinomas (BCCs), 9 squamous cell carcinomas (SCCs)) of the nose, periorbital areas and ears from 40 previously untreated patients (group 1) and 57 patients who had undergone surgery (group 2).
  • We calculated survival rates and assessed functional and cosmetic results de visu.
  • Conclusion. - Brachytherapy provided a high level of local control and good cosmetic results for facial periorificial skin carcinomas that pose problems of surgical reconstruction.
  • [MeSH-major] Brachytherapy. Carcinoma, Basal Cell / radiotherapy. Carcinoma, Squamous Cell / radiotherapy. Ear Neoplasms / radiotherapy. Ear, External. Eyelid Neoplasms / radiotherapy. Nose Neoplasms / radiotherapy. Skin Neoplasms / radiotherapy

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16529964.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


17. McPherson T, Ogg G: Spontaneous resolution of basal cell carcinoma in naevoid basal cell carcinoma syndrome/Gorlin's syndrome. Clin Exp Dermatol; 2009 Dec;34(8):e884-5
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spontaneous resolution of basal cell carcinoma in naevoid basal cell carcinoma syndrome/Gorlin's syndrome.
  • We describe a 10-year-old patient with naevoid basal cell carcinoma syndrome (NBCCS) which was diagnosed when she was 3 years old.
  • She has developed multiple basal cell carcinomas (BCCs) over this time, in particular on her face and trunk.
  • [MeSH-major] Basal Cell Nevus Syndrome / pathology. Carcinoma, Basal Cell / pathology. Skin Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20055856.001).
  • [ISSN] 1365-2230
  • [Journal-full-title] Clinical and experimental dermatology
  • [ISO-abbreviation] Clin. Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


18. Diluvio L, Campione E, Paternò EJ, Orlandi A, Terrinoni A, Chimenti S: Peculiar clinical and dermoscopic remission pattern following imiquimod therapy of basal cell carcinoma in seborrhoeic areas of the face. J Dermatolog Treat; 2009;20(2):124-9
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peculiar clinical and dermoscopic remission pattern following imiquimod therapy of basal cell carcinoma in seborrhoeic areas of the face.
  • Imiquimod is a 240.3-Da synthetic imidazoquinolinamine (C14H16N4), developed in 1983 and approved in 1997 by the US Food and Drug Administration for the topical treatment of external genital and perianal warts and, more recently, also for actinic keratosis and superficial basal cell carcinomas.
  • We report five cases of patients affected by basal cell carcinomas localized in seborrhoeic areas of the face, successfully treated with topical imiquimod and characterized by the occurrence of eruptive epidermoid cysts at the end-point of therapy.
  • The dermatoscopic evaluation disclosed the presence in all lesions of a common feature characterized by a hyperkeratotic yellow-withish area, resembling 'popcorn', excluding dermoscopic basal cell carcinoma features.
  • Furthermore, histological proof confirmed the diagnosis of epidermoid cysts.
  • As reported in the literature and as observed in our clinical experience, the occurrence of epidermoid cysts, after the topical treatment of basal cell carcinomas with imiquimod, may represent a local immune reaction that is drug-related and is a typical remission pattern in particular anatomical areas.
  • We also emphasized the usefulness of dermoscopy in supporting the clinical diagnosis of epidermoid cysts, excluding the presence of tumoural residue or recurrence.
  • [MeSH-major] Aminoquinolines / therapeutic use. Carcinoma, Basal Cell / drug therapy. Carcinoma, Basal Cell / pathology. Skin Neoplasms / drug therapy. Skin Neoplasms / pathology
  • [MeSH-minor] Administration, Cutaneous. Aged. Antineoplastic Agents / therapeutic use. Biopsy, Needle. Dermoscopy / methods. Dose-Response Relationship, Drug. Drug Administration Schedule. Face. Female. Follow-Up Studies. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Staging. Risk Assessment. Sampling Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18991155.001).
  • [ISSN] 1471-1753
  • [Journal-full-title] The Journal of dermatological treatment
  • [ISO-abbreviation] J Dermatolog Treat
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 99011-02-6 / imiquimod
  •  go-up   go-down


19. van der Geer S, Ostertag JU, Krekels GA: Treatment of basal cell carcinomas in patients with nevoid basal cell carcinoma syndrome. J Eur Acad Dermatol Venereol; 2009 Mar;23(3):308-13
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of basal cell carcinomas in patients with nevoid basal cell carcinoma syndrome.
  • BACKGROUND: Nevoid basal cell carcinoma syndrome (NBCCS) is characterized by the development of multiple basal cell carcinomas (BCCs).
  • A major problem for these patients is the enormous amount of BCCs which can invade in the deep underlying structures, especially in the face.
  • [MeSH-major] Basal Cell Nevus Syndrome / therapy. Skin Neoplasms / therapy

  • Genetic Alliance. consumer health - Nevoid basal cell carcinoma syndrome.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19207641.001).
  • [ISSN] 1468-3083
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Aminoquinolines; 99011-02-6 / imiquimod
  • [Number-of-references] 51
  •  go-up   go-down


20. Kanitakis J, Chouvet B: Granular-cell basal cell carcinoma of the skin. Eur J Dermatol; 2005 Jul-Aug;15(4):301-3
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granular-cell basal cell carcinoma of the skin.
  • Granular cell basal cell carcinoma (GBCC) is a very rare variant of BCC, of which ten cases have been reported in the literature.
  • The tumor developed on the face of a 71-year old man and showed typical features of GBCC, i.e. a tumor reminiscent of nodular BCC consisting of cells with a granular eosinophilic cytoplasm.
  • [MeSH-major] Adenocarcinoma / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Aged. Diagnosis, Differential. Humans. Immunohistochemistry. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16048765.001).
  • [ISSN] 1167-1122
  • [Journal-full-title] European journal of dermatology : EJD
  • [ISO-abbreviation] Eur J Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 12
  •  go-up   go-down


21. Wetzig T, Kendler M, Maschke J, Paasch U, Simon JC: No clinical benefit of preoperative fluorescence diagnosis of basal cell carcinoma localized in the H-zone of the face. Br J Dermatol; 2010 Jun;162(6):1370-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] No clinical benefit of preoperative fluorescence diagnosis of basal cell carcinoma localized in the H-zone of the face.
  • BACKGROUND: Basal cell carcinoma (BCC) is the most common malignant skin carcinoma.
  • Fluorescence diagnosis (FD) has been suggested as a promising method for noninvasive detection of subclinical tumour cell dissemination in BCC.
  • OBJECTIVES: In this prospective study, we evaluated the clinical performance of a preoperative definition of the lateral borders of BCC by FD in comparison with its definition by purely clinical diagnosis (CD).
  • The fluorescence intensity on the skin was recorded using a digital light-emitting diode-based fluorescence imaging system.
  • [MeSH-major] Carcinoma, Basal Cell / diagnosis. Facial Neoplasms / diagnosis. Fluorescence

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 The Authors. Journal Compilation © 2010 British Association of Dermatologists.
  • (PMID = 20302577.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


22. Gufler H, Franke FE, Rau WS: High-resolution MRI of basal cell carcinomas of the face using a microscopy coil. AJR Am J Roentgenol; 2007 May;188(5):W480-4
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-resolution MRI of basal cell carcinomas of the face using a microscopy coil.
  • OBJECTIVE: The objective of this article is to evaluate the diagnostic accuracy of high-resolution MRI using a microscopy surface coil to stage basal cell carcinomas of the face.
  • [MeSH-major] Carcinoma, Basal Cell / diagnosis. Magnetic Resonance Imaging / methods. Skin Neoplasms / diagnosis
  • [MeSH-minor] Aged. Aged, 80 and over. Face. Female. Humans. Male. Microscopy / instrumentation. Middle Aged. Prospective Studies

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17449748.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Khandwala M, Penmetsa BR, Dey S, Schofield JB, Jones CA, Podoleanu A: Imaging of periocular basal cell carcinoma using en face optical coherence tomography: a pilot study. Br J Ophthalmol; 2010 Oct;94(10):1332-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imaging of periocular basal cell carcinoma using en face optical coherence tomography: a pilot study.
  • AIM: To use en face optical coherence tomographic (OCT) imaging to identify features of tumour tissue and their correlation with histopathologic findings and to assess the effect of different wavelengths and resolutions of OCT in identifying tumour boundaries and features.
  • METHODS: Excision specimens of consecutive biopsy-proven periocular basal cell carcinomas (BCCs) (n=8) were assessed by OCT, performing in vitro cross-section and en face scans of the tissues.
  • CONCLUSION: En face OCT imaging has the potential to identify tumour tissue from healthy tissue.
  • Non-contact OCT imaging of the skin is a non-invasive and convenient method and can be useful for demarcating BCCs on the face and eyelids.
  • Future larger studies on in vivo BCCs using en face ultra-high-resolution OCT should provide information on subtyping BCCs.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Orbital Neoplasms / pathology. Tomography, Optical Coherence / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20516143.001).
  • [ISSN] 1468-2079
  • [Journal-full-title] The British journal of ophthalmology
  • [ISO-abbreviation] Br J Ophthalmol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


24. Altaykan A, Ersoy-Evans S, Erkin G, Ozkaya O: Basal cell carcinoma arising in nevus sebaceous during childhood. Pediatr Dermatol; 2008 Nov-Dec;25(6):616-9
MedlinePlus Health Information. consumer health - Skin Conditions.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma arising in nevus sebaceous during childhood.
  • Nevus sebaceous usually occurs as a solitary lesion located mostly on the scalp and the face.
  • However, few cases of basal cell carcinoma arising in nevus sebaceous before puberty were reported.
  • Herein, we report a case of basal cell carcinoma arising in a nevus sebaceous on the scalp of a 10-year-old boy, and a review of the literature on prepubertal cases and the need for prophylactic surgery.
  • [MeSH-major] Carcinoma, Basal Cell / etiology. Hamartoma / complications. Skin Diseases / complications. Skin Neoplasms / etiology

  • Genetic Alliance. consumer health - Nevus.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19067866.001).
  • [ISSN] 1525-1470
  • [Journal-full-title] Pediatric dermatology
  • [ISO-abbreviation] Pediatr Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Gudi V, Ormerod AD, Dawn G, Green C, MacKie RM, Douglas WS, Gupta G, Scottish Dermatological Society: Management of basal cell carcinoma by surveyed dermatologists in Scotland. Clin Exp Dermatol; 2006 Sep;31(5):648-52
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of basal cell carcinoma by surveyed dermatologists in Scotland.
  • BACKGROUND: The British Association of Dermatologists (BAD) has produced guidelines for management of basal cell carcinoma (BCC) in the UK.
  • A diagnostic biopsy was taken in 22% of lesions, and the rest were treated definitively after a clinical diagnosis of BCC, of which 90% were confirmed on histology.
  • Four of 21 recurrent tumours and 9 of 81 tumours on high-risk areas of the face were managed with curettage and cautery or cryotherapy, rather than surgical excision.
  • [MeSH-major] Carcinoma, Basal Cell. Skin Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16901303.001).
  • [ISSN] 0307-6938
  • [Journal-full-title] Clinical and experimental dermatology
  • [ISO-abbreviation] Clin. Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  •  go-up   go-down


26. Lackey PL, Sargent LA, Wong L, Brzezienski M, Kennedy JW: Giant basal cell carcinoma surgical management and reconstructive challenges. Ann Plast Surg; 2007 Mar;58(3):250-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant basal cell carcinoma surgical management and reconstructive challenges.
  • Basal cell carcinoma is exceedingly common, but tumors >5 cm in size or giant basal cell carcinomas (GBCCs) are rare.
  • With the exception of 1 chest lesion, all GBCCs involved the face or scalp.
  • The 10 large defects were reconstructed with 5 free-tissue transfers, 2 pedicled musculocutaneous flaps, and 3 rotational skin flaps.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Carcinoma, Basal Cell / surgery. Carcinoma, Giant Cell / pathology. Carcinoma, Giant Cell / surgery. Reconstructive Surgical Procedures / methods

  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17471127.001).
  • [ISSN] 0148-7043
  • [Journal-full-title] Annals of plastic surgery
  • [ISO-abbreviation] Ann Plast Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Gulia A, Altamura D, De Trane S, Micantonio T, Fargnoli MC, Peris K: Pigmented reticular structures in basal cell carcinoma and collision tumours. Br J Dermatol; 2010 Feb 1;162(2):442-4
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pigmented reticular structures in basal cell carcinoma and collision tumours.
  • BACKGROUND: The dermatoscopic diagnosis of basal cell carcinoma (BCC) is based on well-known specific criteria.
  • Despite the fact that a pigment network is considered a negative feature for the diagnosis of BCC, its detection in a BCC context has been reported in 2.8% of cases.
  • OBJECTIVES: To determine whether pigment networks or network-like structures might represent a pitfall for the correct diagnosis of BCC.
  • Nine of 14 BCCs presented a typical pigment network, due to the association of a BCC lesion with a naevus, solar lentigo or actinic keratosis; two BCCs located on the face showed a pseudonetwork, and three of 14 lesions displayed a network-like structure characterized by light-brown irregularly meshed short linear structures, histopathologically related to a hyperpigmentation of the basal layer of the epidermis.
  • CONCLUSIONS: The presence of a pigment network in the context of a BCC is uncommon, and it usually reflects the association of BCC with a solar lentigo, naevus or a specific location of the lesion on photodamaged skin.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Dermoscopy / methods. Melanins. Skin Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Humans. Retrospective Studies. Skin Pigmentation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19754866.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Melanins
  •  go-up   go-down


28. Raasch BA, Buettner PG, Garbe C: Basal cell carcinoma: histological classification and body-site distribution. Br J Dermatol; 2006 Aug;155(2):401-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma: histological classification and body-site distribution.
  • BACKGROUND: Basal cell carcinoma (BCC) is the most common cancer worldwide in white-skinned populations.
  • METHODS: A case series of BCC from a prospective population-based register study collecting information on all excised and histologically confirmed skin cancers in Townsville, north Australia between 1997 and 1999.
  • For all histological subtypes and both genders relative tumour density was highest for the face, followed by the neck.
  • CONCLUSIONS: The study found a higher rate of superficial BCC than previous studies from less sun-exposed countries, and a more equal distribution of superficial BCC on face, trunk and limbs.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16882181.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


29. Betti R, Menni S, Radaelli G, Bombonato C, Crosti C: Micronodular basal cell carcinoma: a distinct subtype? Relationship with nodular and infiltrative basal cell carcinomas. J Dermatol; 2010 Jul;37(7):611-6
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Micronodular basal cell carcinoma: a distinct subtype? Relationship with nodular and infiltrative basal cell carcinomas.
  • Micronodular basal cell carcinoma (BCC) may be more difficult to eradicate and prone to recurrence than nodular subtype.
  • The aim of the study was to compare anatomical and histological characteristics of the basal cell carcinomas subtypes and the relationship of the micronodular BCC with other subtypes.
  • In the mid-face/periauricular region, 95.5% of micronodular and 100% of infiltrative cases of were level III or IV, compared to 50% of nodular BCC (P < 0.001).
  • The Clark level of nodular subtype was higher for BCC of mid-face/periauricular than other regions (P < 0.05).
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Nose Neoplasms / pathology. Scalp / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20629826.001).
  • [ISSN] 1346-8138
  • [Journal-full-title] The Journal of dermatology
  • [ISO-abbreviation] J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


30. Raasch B: Management of superficial basal cell carcinoma: focus on imiquimod. Clin Cosmet Investig Dermatol; 2009;2:65-75

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of superficial basal cell carcinoma: focus on imiquimod.
  • Superficial basal cell carcinoma comprise up to 25% of all histological sub-types.
  • Imiquimod 5% cream has been shown to stimulate the innate and cell mediated immune system.
  • The short-term success of imiquimod 5% cream in randomized controlled trials comparing different treatment regimes and dosing as a treatment for small superficial basal cell carcinoma (BCC) not on the face or neck is in the range of 82% for 5 times per week application.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Dermatol. 2001 Apr;144(4):832-40 [11298545.001]
  • [Cites] Br J Dermatol. 2001 Sep;145(3):467-71 [11531838.001]
  • [Cites] Clin Exp Dermatol. 2002 Oct;27(7):571-7 [12464152.001]
  • [Cites] Dermatol Surg. 2003 Jun;29(6):566-71 [12786697.001]
  • [Cites] Arch Dermatol. 2004 Jan;140(1):17-23 [14732655.001]
  • [Cites] Br J Dermatol. 2005 May;152(5):939-47 [15888150.001]
  • [Cites] Genome Biol. 2007;8(1):R8 [17222352.001]
  • [Cites] Dermatol Surg. 2007 May;33(5):579-87 [17451581.001]
  • [Cites] Br J Dermatol. 2007 Dec;157 Suppl 2:8-13 [18067624.001]
  • [Cites] Br J Dermatol. 2007 Dec;157 Suppl 2:34-40 [18067630.001]
  • [Cites] Br J Dermatol. 2007 Dec;157 Suppl 2:47-51 [18067632.001]
  • [Cites] J Exp Med. 2008 Sep 29;205(10):2221-34 [18794336.001]
  • [Cites] J Am Acad Dermatol. 1990 Dec;23(6 Pt 1):1118-26 [2273112.001]
  • [Cites] Clin Radiol. 1986 Jan;37(1):33-4 [3514075.001]
  • [Cites] Clin Plast Surg. 1993 Jan;20(1):131-47 [8420702.001]
  • [Cites] J Am Acad Dermatol. 1997 Jan;36(1):72-7 [8996264.001]
  • [Cites] Br J Cancer. 1997;76(1):100-6 [9218740.001]
  • [Cites] J Dermatol Surg Oncol. 1989 Mar;15(3):315-28 [2646336.001]
  • [Cites] Dermatol Surg. 2000 Jun;26(6):577-8; discussion 578-9 [10848940.001]
  • [Cites] Dermatol Surg. 2000 Aug;26(8):759-64 [10940063.001]
  • [Cites] J Am Acad Dermatol. 2001 May;44(5):807-13 [11312429.001]
  • [Cites] Dermatol Surg. 2002 Apr;28(4):344-6 [11966794.001]
  • [Cites] Dermatol Surg. 2002 May;28(5):427-9 [12030878.001]
  • [Cites] J Am Acad Dermatol. 2002 Sep;47(3):390-8 [12196749.001]
  • [Cites] Br J Dermatol. 2002 Dec;147(6):1227-36 [12452875.001]
  • [Cites] Int J Dermatol. 2002 Nov;41(11):810-6 [12453012.001]
  • [Cites] Dermatol Surg. 2003 Mar;29(3):205-10 [12614409.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2003 Mar;17(2):167-70 [12705745.001]
  • [Cites] BMJ. 2003 Oct 4;327(7418):794-8 [14525881.001]
  • [Cites] Br J Dermatol. 2003 Nov;149 Suppl 66:57-8 [14616353.001]
  • [Cites] Br J Dermatol. 2003 Nov;149 Suppl 66:59-61 [14616354.001]
  • [Cites] J Am Acad Dermatol. 2004 May;50(5):722-33 [15097956.001]
  • [Cites] Lancet. 2004 Nov 13-19;364(9447):1766-72 [15541449.001]
  • [Cites] Arch Dermatol. 2005 Aug;141(8):985-93 [16103328.001]
  • [Cites] Eur J Dermatol. 2005 Sep-Oct;15(5):374-81 [16172048.001]
  • [Cites] N Z Med J. 2005 Oct 7;118(1223):U1682 [16224506.001]
  • [Cites] Australas J Dermatol. 2006 Feb;47(1):1-12 [16405477.001]
  • [Cites] J Drugs Dermatol. 2006 May;5(5):461-4 [16703785.001]
  • [Cites] Aust Fam Physician. 2006 Jun;35(6):455-8 [16751865.001]
  • [Cites] Clin Exp Dermatol. 2006 Sep;31(5):721-2 [16780500.001]
  • [Cites] Br J Dermatol. 2006 Aug;155(2):401-7 [16882181.001]
  • [Cites] Australas J Dermatol. 2006 Nov;47(4):258-65 [17034468.001]
  • [Cites] Cochrane Database Syst Rev. 2007;(1):CD003412 [17253489.001]
  • [Cites] Br J Dermatol. 2007 Apr;156(4):769-71 [17263811.001]
  • [Cites] Arch Dermatol. 2007 Feb;143(2):266-8 [17310012.001]
  • [Cites] Drugs. 2007;67(6):915-34 [17428108.001]
  • [Cites] Int J Dermatol. 2007 May;46(5):539-42 [17472691.001]
  • [Cites] Drugs. 2007;67(15):2187-210 [17927284.001]
  • [Cites] Dermatol Surg. 2008 Jan;34(1):1-7; discussion 8 [18053058.001]
  • [Cites] J Drugs Dermatol. 2008 Jan;7(1 Suppl 1):s3-6 [18277456.001]
  • [Cites] J Drugs Dermatol. 2008 Jan;7(1 Suppl 1):s15-6 [18277458.001]
  • [Cites] J Biomed Opt. 2008 Jan-Feb;13(1):014003 [18315361.001]
  • [Cites] Br J Dermatol. 2008 Jul;159(1):35-48 [18593385.001]
  • [Cites] Eur J Dermatol. 2008 Sep-Oct;18(5):547-53 [18693158.001]
  • [Cites] Eur J Dermatol. 2008 Nov-Dec;18(6):677-82 [18955210.001]
  • [Cites] Br J Plast Surg. 1999 Jan;52(1):24-8 [10343586.001]
  • [Cites] Br J Dermatol. 2000 Dec;143(6):1270-5 [11122032.001]
  • [Cites] J Am Acad Dermatol. 1999 Dec;41(6):1002-7 [10570388.001]
  • [Cites] Arch Dermatol. 1999 Oct;135(10):1177-83 [10522664.001]
  • [Cites] Australas J Dermatol. 2006 Feb;47(1):46-8 [16405483.001]
  • (PMID = 21436969.001).
  • [ISSN] 1178-7015
  • [Journal-full-title] Clinical, cosmetic and investigational dermatology
  • [ISO-abbreviation] Clin Cosmet Investig Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Other-IDs] NLM/ PMC3047930
  • [Keywords] NOTNLM ; imiquimod / skin cancer / superficial basal cell carcinoma
  •  go-up   go-down


31. Rustemeyer J, Thieme V, Günther L, Bremerich A: [Experiences with surgical management of facial basal cell carcinoma and procedures for plastic reconstruction]. Mund Kiefer Gesichtschir; 2005 Jul;9(4):220-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Experiences with surgical management of facial basal cell carcinoma and procedures for plastic reconstruction].
  • BACKGROUND: No recurrences and optimal aesthetic outcomes after R0 resection and plastic reconstruction of the face are the goals in the surgical treatment of basal cell carcinoma.
  • PATIENTS AND METHODS: This study included 205 follow-up patients undergoing R0 resection of primary basal cell carcinoma and facial skin reconstruction between 1998 and 2002; data were analyzed retrospectively.
  • RESULTS: The most frequent locations of basal cell carcinoma were the nasal (40.5%) and orbital (22.9%) regions.
  • Local flaps, full-thickness skin grafts, and sliding flaps were usually performed; indications for split-thickness skin grafts were rare.
  • Disturbances of sensation were found in only 3.6% of the sliding flaps and in 11.7% of the local flaps, but 22.7% in full-thickness and 38.7% in split-thickness skin grafts.
  • The aesthetic outcome, evaluated by clinical inspection and a patient satisfaction score, was classified as "unobtrusive" and "good or excellent" for 88.4% of local flaps, 92.6% of sliding flaps, but only for 66.4% of full-thickness and 54% of split-thickness skin grafts.
  • CONCLUSION: Local flaps and sliding flaps result in better aesthetic and neurological outcomes after reconstruction of facial skin regions.
  • Skin grafts have their indications as an alternative procedure in cases of critical indications for flaps.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Facial Neoplasms / surgery. Postoperative Complications / etiology. Skin Neoplasms / surgery. Surgical Flaps

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mayo Clin Proc. 1992 Oct;67(10):971-80 [1434858.001]
  • [Cites] Arch Dermatol. 2003 May;139(5):643-8 [12756102.001]
  • [Cites] Plast Reconstr Surg. 2000 Jun;105(7):2544-51 [10845311.001]
  • [Cites] Dermatol Surg. 1996 Oct;22(10):854-8 [9246168.001]
  • [Cites] Aust J Public Health. 1994 Jun;18(2):218-21 [7948343.001]
  • [Cites] Int J Dermatol. 2004 Feb;43(2):148-50 [15125510.001]
  • [Cites] BMJ. 2004 Sep 25;329(7468):705 [15364703.001]
  • [Cites] Dermatol Surg. 2000 Aug;26(8):759-64 [10940063.001]
  • [Cites] Arch Facial Plast Surg. 2002 Apr-Jun;4(2):114-9 [12020207.001]
  • [Cites] Arch Dermatol. 2000 Nov;136(11):1318-24 [11074691.001]
  • [Cites] Handchir Mikrochir Plast Chir. 1992 May;24(3):151-8 [1618421.001]
  • [Cites] J Dermatol Surg Oncol. 1991 Sep;17(9):713-8 [1890243.001]
  • [Cites] Aesthetic Plast Surg. 2003 Jul-Aug;27(4):286-92 [15058551.001]
  • [Cites] Arch Dermatol. 2004 Jan;140(1):17-23 [14732655.001]
  • [Cites] Br J Dermatol. 2004 Jul;151(1):141-7 [15270883.001]
  • [Cites] Dermatol Surg. 2000 Apr;26(4):338-40 [10759821.001]
  • [Cites] J Am Acad Dermatol. 1992 May;26(5 Pt 1):754-6 [1583176.001]
  • [Cites] Br J Cancer. 1997;76(1):100-6 [9218740.001]
  • [Cites] Otolaryngol Clin North Am. 1990 Oct;23(5):845-64 [2259505.001]
  • [Cites] J R Coll Physicians Lond. 1987 Apr;21(2):91-6 [3585837.001]
  • [Cites] J Am Acad Dermatol. 1990 Dec;23(6 Pt 1):1114-8 [2273111.001]
  • [Cites] J Am Acad Dermatol. 1985 Mar;12(3):522-5 [3989011.001]
  • [Cites] Br J Dermatol. 1999 Sep;141(3):415-23 [10583044.001]
  • [Cites] Clin Radiol. 1986 Jan;37(1):33-4 [3514075.001]
  • [Cites] J Am Acad Dermatol. 2001 May;44(5):807-13 [11312429.001]
  • (PMID = 15991049.001).
  • [ISSN] 1432-9417
  • [Journal-full-title] Mund-, Kiefer- und Gesichtschirurgie : MKG
  • [ISO-abbreviation] Mund Kiefer Gesichtschir
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


32. Dissemond J, Grabbe S: [Non-surgical therapy of basal cell carcinoma of the head-neck region]. Laryngorhinootologie; 2006 Feb;85(2):133-41; quiz 142-3
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Non-surgical therapy of basal cell carcinoma of the head-neck region].
  • Basal cell carcinoma is a semi-malignant epithelial skin tumour with a locally destructive growth pattern but a very low tendency to metastases.
  • Basal cell carcinoma represent the most frequent malignant cutaneous tumour worldwide in white population with a lifetime risk of 30 % and still increasing incidence.
  • Basal cell carcinoma are predominantly located in the central region of the face.
  • The very rarely observed occurrence of metastases seems to be a result of insufficient therapy or a metatypic basal cell carcinoma type.
  • Therapy of first choice of basal cell carcinoma is the complete, micrographically controlled excision.
  • [MeSH-major] Carcinoma, Basal Cell / therapy. Skin Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DICLOFENAC .
  • Hazardous Substances Data Bank. UREA .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16498544.001).
  • [ISSN] 0935-8943
  • [Journal-full-title] Laryngo- rhino- otologie
  • [ISO-abbreviation] Laryngorhinootologie
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Aminoquinolines; 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Antineoplastic Agents; 0 / Interferon Inducers; 0 / Ointments; 144O8QL0L1 / Diclofenac; 8W8T17847W / Urea; 9008-11-1 / Interferons; 99011-02-6 / imiquimod
  • [Number-of-references] 15
  •  go-up   go-down


33. Szabo B, Szabo I, Mera M, Fripcea AM: [Keratotic basal cell carcinoma with orbital extension--case report]. Oftalmologia; 2005;49(2):43-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Keratotic basal cell carcinoma with orbital extension--case report].
  • This is a description of a case of a 72-year-old female who developed a basal cell carcinoma of the external angle of the eyelid, with intraorbital extension.
  • This type of cancer of the eyelid developed on keratotic skin lesions of the face; the invasion of the orbit occurred only for two years.
  • [MeSH-major] Carcinoma, Basal Cell / etiology. Eyelid Neoplasms / etiology. Keratosis / complications. Orbital Neoplasms / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16245743.001).
  • [ISSN] 1220-0875
  • [Journal-full-title] Oftalmologia (Bucharest, Romania : 1990)
  • [ISO-abbreviation] Oftalmologia
  • [Language] rum
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


34. Lemierre G, Bony-Rerolle S, El-Haïté A, Auquit-Auckbur I, Milliez PY: [Recurrence of a basal cell carcinoma in a skin graft in spite of total excision. A case report]. Ann Chir Plast Esthet; 2007 Feb;52(1):71-4
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Recurrence of a basal cell carcinoma in a skin graft in spite of total excision. A case report].
  • [Transliterated title] Apparente récidive d'un carcinome basocellulaire de la face au sein d'une greffe de peau totale malgré une exérèse complète. A propos d'un cas.
  • The authors report an original case of a recurrence of basal cell carcinoma in a skin graft recipient site.
  • The skin graft was used to resurface the defect following complete excision of basal cell carcinoma in the mandibular angle area.
  • Three answers can be given to the question of the origin of that new carcinoma: recurrence of the primary carcinoma, metastasis to a lymph node or a transfer of a basal cell carcinoma located into the skin graft which grew further.
  • This last hypothesis remains the most probable because the histology of the two carcinomas was different and that the patient presented many others locations of basal cell carcinomas.
  • Skin grafted areas must be checked for recurrence of basal cell carcinoma in such patients because invisible basal cell carcinoma can be transferred within the graft where they can grow for their own.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Neoplasm Recurrence, Local / pathology. Skin Neoplasms / pathology. Surgical Flaps

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17126980.001).
  • [ISSN] 0294-1260
  • [Journal-full-title] Annales de chirurgie plastique et esthétique
  • [ISO-abbreviation] Ann Chir Plast Esthet
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


35. Mehta V, Balachandran C: Pigmented basal cell carcinoma successfully treated with 5% Imiquimod cream. Indian J Dermatol; 2008;53(3):140-1

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pigmented basal cell carcinoma successfully treated with 5% Imiquimod cream.
  • Basal cell carcinoma (BCC) is the most common malignant skin tumor, amongst which the nodular, nodulo ulcerative and superficial types comprise nearly 80% of all BCCs.
  • We report our experience of treatment a large pigmented BCC on the face with topical Imiquimod 5% cream.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Indian J Dermatol Venereol Leprol. 2006 Nov-Dec;72(6):466-9 [17179631.001]
  • [Cites] Dermatol Online J. 2004;10(1):4 [15347486.001]
  • [Cites] J Am Acad Dermatol. 2001 May;44(5):807-13 [11312429.001]
  • [Cites] Br J Dermatol. 2002 Dec;147(6):1227-36 [12452875.001]
  • [Cites] J Am Acad Dermatol. 2002 Sep;47(3):390-8 [12196749.001]
  • [Cites] Int J Dermatol. 2002 Nov;41(11):810-6 [12453012.001]
  • (PMID = 19882014.001).
  • [ISSN] 1998-3611
  • [Journal-full-title] Indian journal of dermatology
  • [ISO-abbreviation] Indian J Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2763750
  • [Keywords] NOTNLM ; Basal cell carcinoma / Imiquimod / pigmented / treatment
  •  go-up   go-down


36. Bariani RL, Nahas FX, Barbosa MV, Farah AB, Ferreira LM: Basal cell carcinoma: an updated epidemiological and therapeutically profile of an urban population. Acta Cir Bras; 2006 Mar-Apr;21(2):66-73
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma: an updated epidemiological and therapeutically profile of an urban population.
  • PURPOSE: To describe the epidemiological profile of basal cell carcinoma patients at a private hospital in São Paulo and to evaluate the treatment adopted.
  • METHODS: A prospective study of 202 patients, on which 253 lesions were diagnosed for histopathological exam as basal cell carcinoma within the period of January 2001 to September 2003, in the Plastic Surgery Residency Program at the Hospital Jaraguá.
  • RESULTS: The incidence of basal cell carcinoma was 126 cases per 100,000 patients in a period of 32 months (36 cases per 100,000 patients/year).
  • Exposition to ultraviolet radiation was reported by 77% of the patients and the most frequent location of tumors was on the face (71.2% of the cases).
  • Actinic keratosis and a history of skin cancer were reported in 43.6% and in 25% of the cases, respectively.
  • CONCLUSIONS: The factors related to the development of basal cell cancer which were significantly present in the population surveyed were: older age, white individuals, phototypes I and II, presence of actinic keratosis, previous history of non-melanoma skin cancer and exposure to ultra-violet rays both in recreational and in occupational form.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16583057.001).
  • [ISSN] 0102-8650
  • [Journal-full-title] Acta cirurgica brasileira
  • [ISO-abbreviation] Acta Cir Bras
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


37. Marra DE, Torres A, Schanbacher CF, Gonzalez S: Detection of residual basal cell carcinoma by in vivo confocal microscopy. Dermatol Surg; 2005 May;31(5):538-41
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of residual basal cell carcinoma by in vivo confocal microscopy.
  • BACKGROUND: Near-infrared reflectance-mode confocal scanning laser microscopy (RCM) represents a novel imaging technique for microscopic analysis of skin lesions and may provide a noninvasive modality for the diagnosis of basal cell carcinoma (BCC).
  • CONCLUSION: We report the use of RCM in the confirmation of residual BCC in two cases and the tentative diagnosis with subsequent pathologic conformation of a third case in which a biopsy was previously inadequate.
  • Our results demonstrate that confocal microscopy may facilitate diagnosis of BCC in vivo and warrant further prospective study to quantify the sensitivity and specificity of this rapidly evolving imaging modality.
  • [MeSH-major] Carcinoma, Basal Cell / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Aged. Arm. Diagnosis, Differential. Face. Forehead. Humans. Male. Microscopy, Confocal. Middle Aged. Pilot Projects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15962737.001).
  • [ISSN] 1076-0512
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Alkalay R, Alcalay J, Maly A, Ingber A, Fritsch C, Ruzicka T, Enk CD: Fluorescence imaging for the demarcation of basal cell carcinoma tumor borders. J Drugs Dermatol; 2008 Nov;7(11):1033-7
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fluorescence imaging for the demarcation of basal cell carcinoma tumor borders.
  • BACKGROUND: Basal cell carcinoma (BCC) is a common malignancy accounting for 80% of all nonmelanoma skin cancers.
  • Fluorescence imaging following application of 5-aminolevulinic acid is a noninvasive diagnostic technique that gives rapid information about the superficial extent of the skin tumor.
  • METHODS: Eighteen patients with histologically verified nodular BCCs on the face scheduled for MMS were included in the study.
  • The following morning, tumor borders were determined clinically (clinical size), after illumination with Wood's light (fluorescence size), and by the tumor defect left on the skin surface following removal of the MMS specimen (Mohs size).
  • [MeSH-major] Microscopy, Fluorescence. Neoplasms, Basal Cell / pathology. Skin Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19110733.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Fluorescent Dyes
  •  go-up   go-down


39. Pincus LB, McCalmont TH, Neuhaus IM, Kasper R, Oh DH: Basal cell carcinomas arising within multiple trichoepitheliomas. J Cutan Pathol; 2008 Oct;35 Suppl 1:59-64
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinomas arising within multiple trichoepitheliomas.
  • We describe a 57-year-old male with numerous skin-colored firm papules and plaques present on the central face since 6 years of age.
  • Biopsies from multiple lesions showed TEs both alone and associated with basal cell carcinoma (BCC) in the same section, suggesting the secondary development of BCCs within TEs.
  • Awareness of the potential for the evolution of carcinoma in patients with MFT is important in the management of these patients.
  • [MeSH-major] Carcinoma / pathology. Carcinoma, Basal Cell / pathology. Neoplasms, Adnexal and Skin Appendage / pathology. Neoplasms, Multiple Primary / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright Blackwell Munksgaard 2008.
  • (PMID = 18544067.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Keratin-20; 0 / Proto-Oncogene Proteins c-bcl-2
  •  go-up   go-down


40. Lo Muzio L: Nevoid basal cell carcinoma syndrome (Gorlin syndrome). Orphanet J Rare Dis; 2008;3:32
Genetic Alliance. consumer health - Nevoid basal cell carcinoma syndrome.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nevoid basal cell carcinoma syndrome (Gorlin syndrome).
  • Nevoid basal cell carcinoma syndrome (NBCCS), also known as Gorlin syndrome, is a hereditary condition characterized by a wide range of developmental abnormalities and a predisposition to neoplasms.
  • Main clinical manifestations include multiple basal cell carcinomas (BCCs), odontogenic keratocysts of the jaws, hyperkeratosis of palms and soles, skeletal abnormalities, intracranial ectopic calcifications, and facial dysmorphism (macrocephaly, cleft lip/palate and severe eye anomalies).
  • BCCs (varying clinically from flesh-colored papules to ulcerating plaques and in diameter from 1 to 10 mm) are most commonly located on the face, back and chest.
  • Clinical diagnosis relies on specific criteria.
  • Gene mutation analysis confirms the diagnosis.
  • Antenatal diagnosis is feasible by means of ultrasound scans and analysis of DNA extracted from fetal cells (obtained by amniocentesis or chorionic villus sampling).
  • [MeSH-major] Basal Cell Nevus Syndrome
  • [MeSH-minor] Adolescent. Adult. Bone Neoplasms / epidemiology. Bone Neoplasms / genetics. Bone Neoplasms / pathology. Bone and Bones / abnormalities. Bone and Bones / radiography. Cerebellar Neoplasms / epidemiology. Cerebellar Neoplasms / genetics. Cerebellar Neoplasms / pathology. Child. Female. Humans. Male. Medulloblastoma / epidemiology. Medulloblastoma / genetics. Medulloblastoma / pathology. Odontogenic Cysts / epidemiology. Odontogenic Cysts / genetics. Odontogenic Cysts / pathology. Skin Neoplasms / epidemiology. Skin Neoplasms / genetics. Skin Neoplasms / pathology. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Invest Dermatol. 2003 Sep;121(3):478-81 [12925203.001]
  • [Cites] Clin Exp Dermatol. 2003 Nov;28 Suppl 1:19-23 [14616807.001]
  • [Cites] Dermatol Surg. 2003 Dec;29(12):1236-40 [14725671.001]
  • [Cites] Cancer Res. 2004 Feb 1;64(3):934-41 [14871823.001]
  • [Cites] Arch Pathol Lab Med. 2004 Mar;128(3):313-7 [14987156.001]
  • [Cites] Int J Oral Maxillofac Surg. 2004 Jul;33(5):458-62 [15183409.001]
  • [Cites] J Dermatolog Treat. 2004 Apr;15(2):120-1 [15204165.001]
  • [Cites] Clin Exp Dermatol. 2004 Sep;29(5):542-4 [15347344.001]
  • [Cites] Hum Mutat. 2004 Nov;24(5):441 [15459969.001]
  • [Cites] Arch Fr Pediatr. 1968 Nov;25(9):1083-93 [5728392.001]
  • [Cites] Med Hist. 1969 Jul;13(3):294-7 [4893629.001]
  • [Cites] J Neurosurg. 1971 Nov;35(5):577-84 [5000945.001]
  • [Cites] Birth Defects Orig Artic Ser. 1971 Jun;7(8):140-8 [4950929.001]
  • [Cites] Acta Pathol Microbiol Scand A. 1976 Jan;84(1):107-12 [1251730.001]
  • [Cites] J Neurosurg. 1979 Jan;50(1):100-2 [758369.001]
  • [Cites] Cancer. 1979 Dec;44(6):2294-305 [509397.001]
  • [Cites] Br J Oral Surg. 1979 Nov;17(2):135-46 [298837.001]
  • [Cites] Hautarzt. 1981 Sep;32(9):455-8 [7275582.001]
  • [Cites] Cancer. 1982 Jan 15;49(2):350-3 [7053833.001]
  • [Cites] J Am Acad Dermatol. 1982 Apr;6(4 Pt 2 Suppl):815-23 [6950957.001]
  • [Cites] Ann Neurol. 1982 Apr;11(4):372-6 [7103417.001]
  • [Cites] Wien Klin Wochenschr. 1982 Sep 3;94(16):430-4 [7147982.001]
  • [Cites] Med Pediatr Oncol. 1983;11(3):178-9 [6855699.001]
  • [Cites] Am J Surg Pathol. 1984 Mar;8(3):231-6 [6703200.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1984 Feb;47(2):210-2 [6707662.001]
  • [Cites] Can Med Assoc J. 1985 May 1;132(9):1037-8 [3986729.001]
  • [Cites] N Engl J Med. 1986 Mar 13;314(11):700-6 [3951494.001]
  • [Cites] J Am Acad Dermatol. 1986 Nov;15(5 Pt 1):1023-30 [3537024.001]
  • [Cites] Medicine (Baltimore). 1987 Mar;66(2):98-113 [3547011.001]
  • [Cites] J Am Acad Dermatol. 1987 May;16(5 Pt 1):964-70 [3584581.001]
  • [Cites] J Comput Assist Tomogr. 1987 Sep-Oct;11(5):901-4 [3655059.001]
  • [Cites] Br J Plast Surg. 1987 Sep;40(5):528-31 [3676586.001]
  • [Cites] Am J Med Genet. 1997 Mar 31;69(3):299-308 [9096761.001]
  • [Cites] Am J Med Genet. 1997 Mar 31;69(3):309-14 [9096762.001]
  • [Cites] Cancer Res. 1997 Jun 15;57(12):2369-72 [9192811.001]
  • [Cites] Eur J Gynaecol Oncol. 2006;27(5):519-22 [17139991.001]
  • [Cites] Childs Nerv Syst. 2007 Jan;23(1):133-6 [16977487.001]
  • [Cites] Clin Exp Dermatol. 2007 Mar;32(2):202-3 [16780502.001]
  • [Cites] J Neurosurg. 2006 Oct;105(4 Suppl):315-20 [17328283.001]
  • [Cites] J Am Acad Dermatol. 2007 Aug;57(2 Suppl):S36-7 [17637368.001]
  • [Cites] Am J Otolaryngol. 2007 Sep-Oct;28(5):360-2 [17826543.001]
  • [Cites] J Drugs Dermatol. 2007 Sep;6(9):910-4 [17941362.001]
  • [Cites] Hum Genet. 2007 Dec;122(5):459-66 [17703323.001]
  • [Cites] Br J Cancer. 1997;76(2):141-5 [9231911.001]
  • [Cites] Ann Plast Surg. 1997 Oct;39(4):366-73 [9339279.001]
  • [Cites] Am J Med Genet. 1997 Dec 19;73(3):304-7 [9415689.001]
  • [Cites] Curr Opin Pediatr. 1997 Dec;9(6):630-5 [9425597.001]
  • [Cites] Hum Genet. 1997 Dec;101(3):317-22 [9439661.001]
  • [Cites] Laryngoscope. 1998 Feb;108(2):280-3 [9473082.001]
  • [Cites] Pediatr Hematol Oncol. 1998 Mar-Apr;15(2):187-91 [9592846.001]
  • [Cites] J Am Acad Dermatol. 1998 Aug;39(2 Pt 3):S82-5 [9703130.001]
  • [Cites] Hum Mol Genet. 1999 Feb;8(2):291-7 [9931336.001]
  • [Cites] Clin Genet. 1999 Jan;55(1):34-40 [10066029.001]
  • [Cites] J Am Dent Assoc. 1999 May;130(5):669-74 [10332131.001]
  • [Cites] Dermatologica. 1963;126:106-23 [13954184.001]
  • [Cites] N Engl J Med. 1960 May 5;262:908-12 [13851319.001]
  • [Cites] Genet Med. 2004 Nov-Dec;6(6):495-502 [15545745.001]
  • [Cites] Genet Med. 2004 Nov-Dec;6(6):530-9 [15545751.001]
  • [Cites] Ear Nose Throat J. 2004 Oct;83(10):716-8 [15586876.001]
  • [Cites] Ann Hum Genet. 2004 Nov;68(Pt 6):536-45 [15598212.001]
  • [Cites] Ann Plast Surg. 2004 Dec;53(6):593-5 [15602259.001]
  • [Cites] Arch Dermatol Res. 2005 Jan;296(7):303-8 [15565302.001]
  • [Cites] Neurol Med Chir (Tokyo). 2004 Dec;44(12):665-8 [15684600.001]
  • [Cites] Am J Med Genet A. 2005 Jan 30;132A(3):324-8 [15690381.001]
  • [Cites] Hum Mutat. 2005 Mar;25(3):322-3 [15712338.001]
  • [Cites] J Am Acad Dermatol. 2005 Nov;53(5 Suppl 1):S256-9 [16227103.001]
  • [Cites] Genet Med. 2005 Nov-Dec;7(9):611-9 [16301862.001]
  • [Cites] Prenat Diagn. 2005 Nov;25(11):997-9 [16231297.001]
  • [Cites] J Pathol. 2006 Jan;208(1):17-25 [16294371.001]
  • [Cites] Echocardiography. 2006 Jan;23(1):79-80 [16412193.001]
  • [Cites] Hum Mutat. 2006 Mar;27(3):215-9 [16419085.001]
  • [Cites] Ann Dermatol Venereol. 2006 Feb;133(2):117-23 [16508594.001]
  • [Cites] Tex Heart Inst J. 2006;33(1):88-90 [16572881.001]
  • [Cites] J Med Genet. 2006 Apr;43(4):e16 [16582078.001]
  • [Cites] Tumour Biol. 2006;27(4):175-80 [16675912.001]
  • [Cites] Lasers Surg Med. 2006 Jun;38(5):417-26 [16788928.001]
  • [Cites] Cancer Res. 2006 Jul 15;66(14):6964-71 [16849540.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2006 Aug;20(7):877-8 [16898919.001]
  • [Cites] Br J Cancer. 2006 Aug 21;95(4):548-53 [16909134.001]
  • [Cites] J Dent Res. 2006 Sep;85(9):859-63 [16931872.001]
  • [Cites] Dermatol Ther. 2006 Sep-Oct;19(5):306-14 [17014486.001]
  • [Cites] Dermatol Surg. 2002 Mar;28(3):287-90 [11896785.001]
  • [Cites] Oral Oncol. 2002 Jun;38(4):323-31 [12076694.001]
  • [Cites] Am J Med Genet. 2002 Jul 15;110(4):400-3 [12116218.001]
  • [Cites] Mol Genet Metab. 2002 May;76(1):57-61 [12175781.001]
  • [Cites] Hum Mutat. 2002 Sep;20(3):233-4 [12204003.001]
  • [Cites] J Dermatolog Treat. 2002 Sep;13(3):123-7 [12227875.001]
  • [Cites] Eur J Dermatol. 2002 Nov-Dec;12(6):569-72 [12459530.001]
  • [Cites] Jpn J Clin Oncol. 2003 Jan;33(1):47-50 [12604725.001]
  • [Cites] Clin Nucl Med. 2002 Dec;27(12):913-4 [12607884.001]
  • [Cites] Hum Mutat. 2003 Apr;21(4):451-2 [12655573.001]
  • [Cites] Am J Obstet Gynecol. 2003 Apr;188(4):1093-5 [12712116.001]
  • [Cites] J Am Acad Dermatol. 2003 May;48(5 Suppl):S64-6 [12734479.001]
  • [Cites] Pediatr Neurol. 2003 Mar;28(3):231-4 [12770681.001]
  • [Cites] Neuroradiology. 2003 Jun;45(6):390-2 [12756507.001]
  • [Cites] Cancer. 2003 Aug 1;98(3):618-24 [12879481.001]
  • [Cites] Nat Clin Pract Oncol. 2006 Oct;3(10):575-80 [17019435.001]
  • [Cites] J Clin Pathol. 2006 Oct;59(10):1084-6 [17021131.001]
  • [Cites] J Am Acad Dermatol. 2006 Nov;55(5 Suppl):S86-9 [17052541.001]
  • [Cites] Am J Med Genet A. 2006 Dec 1;140(23):2625-30 [16906569.001]
  • [Cites] AJNR Am J Neuroradiol. 2000 Apr;21(4):790-4 [10782799.001]
  • [Cites] Brain Dev. 2000 Jun;22(4):272-4 [10838118.001]
  • [Cites] J Mol Med (Berl). 2000;78(3):140-6 [10868476.001]
  • [Cites] J Dent Res. 2000 Jun;79(6):1418-22 [10890722.001]
  • [Cites] Cutis. 2000 Jul;66(1):35-8 [10916689.001]
  • [Cites] Arch Dermatol Res. 2000 Sep;292(9):475-6 [11000293.001]
  • [Cites] Br Dent J. 2001 Apr 14;190(7):349-50 [11338037.001]
  • [Cites] J Dermatol Sci. 2001 Sep;27(1):21-6 [11457640.001]
  • [Cites] Dermatologica. 1987;175 Suppl 1:138-44 [3480250.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1987 Dec;64(6):727-30 [3480489.001]
  • [Cites] J Oral Pathol. 1988 Jan;17(1):39-42 [3131508.001]
  • [Cites] J Am Dent Assoc. 1988 Jun;116(7):887-9 [3164743.001]
  • [Cites] J Am Acad Dermatol. 1988 Jul;19(1 Pt 2):176-85 [3165982.001]
  • [Cites] Presse Med. 1988 Nov 26;17(42):2247-50 [2974590.001]
  • [Cites] Dentomaxillofac Radiol. 1987;16(2):99-103 [3333752.001]
  • [Cites] J Oral Maxillofac Surg. 1989 Jun;47(6):629-33 [2656943.001]
  • [Cites] J Am Acad Dermatol. 1989 Jul;21(1):144-5 [2745766.001]
  • [Cites] J Oral Maxillofac Surg. 1989 Aug;47(8):870-3 [2664107.001]
  • [Cites] J Dermatol Surg Oncol. 1989 Aug;15(8):868-71 [2754091.001]
  • [Cites] Int Surg. 1991 Jan-Mar;76(1):64-6 [2045256.001]
  • [Cites] Pediatr Radiol. 1991;21(3):234-5 [2047170.001]
  • [Cites] Genet Couns. 1990;1(3-4):273-7 [2098052.001]
  • [Cites] Am J Med Genet. 1991 Aug 1;40(2):206-10 [1910262.001]
  • [Cites] Br J Cancer. 1991 Nov;64(5):959-61 [1931625.001]
  • [Cites] Br J Neurosurg. 1991;5(6):643-6 [1772613.001]
  • [Cites] Lancet. 1992 Mar 7;339(8793):581-2 [1347096.001]
  • [Cites] Cancer Res. 1992 Mar 15;52(6):1494-8 [1540957.001]
  • [Cites] Genet Couns. 1991;2(3):157-62 [1801852.001]
  • [Cites] Cell. 1992 Apr 3;69(1):111-7 [1348213.001]
  • [Cites] Pediatr Pathol. 1992 Mar-Apr;12(2):255-62 [1570241.001]
  • [Cites] Pediatr Pathol. 1992 May-Jun;12(3):441-7 [1409143.001]
  • [Cites] Cesk Pediatr. 1993 Mar;48(3):129-32 [8495514.001]
  • [Cites] Dermatology. 1993;186(4):311-2 [8513207.001]
  • [Cites] J Med Genet. 1993 Jun;30(6):460-4 [8326488.001]
  • [Cites] Am J Hum Genet. 1993 Sep;53(3):760-7 [8352281.001]
  • [Cites] Hum Mol Genet. 1994 Mar;3(3):447-8 [8012356.001]
  • [Cites] Am J Med Genet. 1994 Apr 15;50(3):272-81 [8042672.001]
  • [Cites] Am J Med Genet. 1994 Apr 15;50(3):282-90 [8042673.001]
  • [Cites] Lancet. 1994 Aug 13;344(8920):477 [7914587.001]
  • [Cites] Bol Asoc Med P R. 1993 Jan-Mar;85(1-3):24-6 [8060441.001]
  • [Cites] Prenat Diagn. 1994 Aug;14(8):725-7 [7991513.001]
  • [Cites] Genomics. 1994 Aug;22(3):505-11 [8001963.001]
  • [Cites] Am J Pathol. 1995 Feb;146(2):472-80 [7856756.001]
  • [Cites] Pediatr Dermatol. 1994 Dec;11(4):323-6 [7899182.001]
  • [Cites] Dermatol Clin. 1995 Jan;13(1):113-25 [7712637.001]
  • [Cites] Br J Radiol. 1995 Apr;68(808):361-8 [7795971.001]
  • [Cites] Br J Radiol. 1995 Jun;68(810):596-9 [7627481.001]
  • [Cites] Nat Genet. 1996 Jan;12(1):85-7 [8528259.001]
  • [Cites] Arch Dermatol. 1996 Jan;132(1):94-5 [8546496.001]
  • [Cites] Neurology. 1996 Feb;46(2):574-6 [8614540.001]
  • [Cites] Science. 1996 Jun 14;272(5268):1668-71 [8658145.001]
  • [Cites] Cell. 1996 Jun 14;85(6):841-51 [8681379.001]
  • [Cites] Br J Ophthalmol. 1996 Apr;80(4):378 [8703894.001]
  • [Cites] Eur J Cancer B Oral Oncol. 1996 May;32B(3):202-6 [8762878.001]
  • [Cites] Nat Genet. 1996 Sep;14(1):7-8 [8782809.001]
  • [Cites] Nat Genet. 1996 Sep;14(1):78-81 [8782823.001]
  • [Cites] Histopathology. 1996 Sep;29(3):247-52 [8884353.001]
  • [Cites] Nature. 1996 Nov 14;384(6605):129-34 [8906787.001]
  • [Cites] J Neurosurg. 1997 Feb;86(2):286-8 [9010431.001]
  • [Cites] Cancer Res. 1997 Mar 1;57(5):842-5 [9041183.001]
  • (PMID = 19032739.001).
  • [ISSN] 1750-1172
  • [Journal-full-title] Orphanet journal of rare diseases
  • [ISO-abbreviation] Orphanet J Rare Dis
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 164
  • [Other-IDs] NLM/ PMC2607262
  •  go-up   go-down


41. Chapas AM, Gilchrest BA: Broad area photodynamic therapy for treatment of multiple basal cell carcinomas in a patient with nevoid basal cell carcinoma syndrome. J Drugs Dermatol; 2006 Feb;5(2 Suppl):3-5
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Broad area photodynamic therapy for treatment of multiple basal cell carcinomas in a patient with nevoid basal cell carcinoma syndrome.
  • We report a case of a 73-year-old man with nevoid basal cell carcinoma syndrome who was referred to us with multiple basal cell carcinomas on his face and chest.
  • The patient underwent photodynamic therapy utilizing a 1-hour incubation of Levulan Kerastick delta-aminolevulinic acid 20% topical solution applied to the full face and illumination with a BLU-U blue light source (10 J/cm2) every 2 to 3 months for a total of 4 treatments.
  • This treatment strategy resulted in multiple benefits, including reducing the number and size of his existing basal cell carcinomas, improving the appearance of previous surgical scars, and decreasing the rate of tumor development.
  • [MeSH-major] Aminolevulinic Acid / therapeutic use. Carcinoma, Basal Cell / drug therapy. Photochemotherapy / methods. Photosensitizing Agents / therapeutic use. Skin Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Nevoid basal cell carcinoma syndrome.
  • Genetic Alliance. consumer health - Basal Cell Carcinoma, Multiple.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16485873.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


42. Filho LL, de Oliveira de Avelar Alchorne A, Pereira GC, Lopes LR, de Carvalho TC: Histological and immunohistochemical evaluation of basal cell carcinoma following curettage and electrodessication. Int J Dermatol; 2008 Jun;47(6):610-4
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histological and immunohistochemical evaluation of basal cell carcinoma following curettage and electrodessication.
  • BACKGROUND: Basal cell carcinoma (BCC) is the most frequent non-melanoma skin cancer.
  • METHODS: 20 primary BCC outpatients were studied at the Dermatology Service of Getúlio Vargas Hospital in the city of Teresina--State of Piauí--Brazil, with lesions of up to 1 cm in diameter on the face, and up to 1.5 cm elsewhere, and with no clinical signs of sclerosing and micronodular forms.
  • CONCLUSIONS: The persistence of tumoral residues after 2 curettage and electrofulguration cycles for basal cell carcinoma was found in 5 sites treated (25%).
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Curettage. Electrosurgery. Skin Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18477158.001).
  • [ISSN] 1365-4632
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / human epithelial antigen-125
  •  go-up   go-down


43. Farhi D, Dupin N, Palangié A, Carlotti A, Avril MF: Incomplete excision of basal cell carcinoma: rate and associated factors among 362 consecutive cases. Dermatol Surg; 2007 Oct;33(10):1207-14
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incomplete excision of basal cell carcinoma: rate and associated factors among 362 consecutive cases.
  • BACKGROUND: Reported rates of incomplete excision of basal cell carcinoma (BCC) range from 4% to 16.6%.
  • A total of 52.7% of the 362 BCCs were located on the face (including nose, 10%; eyelids, 4.2%; lips, 2%; and ears, 2.2%).
  • CONCLUSION: Pathologically reported incomplete excision rate was comparable to that of other studies and was significantly associated with the location on the face, particularly on the nose and inner canthus, and with infiltrative and multifocal histologic types.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Neoplasm Recurrence, Local / surgery. Outcome Assessment (Health Care). Skin Neoplasms / surgery. Surgical Procedures, Operative / standards

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • MedlinePlus Health Information. consumer health - Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17903153.001).
  • [ISSN] 1076-0512
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


44. Jones M, Bresch M, Alvarez D, Böer A: Keloidal basal cell carcinoma: not a distinctive clinicopathological entity. Br J Dermatol; 2009 Jan;160(1):127-31
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Keloidal basal cell carcinoma: not a distinctive clinicopathological entity.
  • BACKGROUND: Keloidal basal cell carcinoma (BCC) has been reported as a rare but distinctive variant of BCC.
  • METHODS: Over 12 months, all cases of BCC with thick sclerotic collagen were collected and studied for clinical diagnosis, site, histopathological features and immunohistochemistry (collagen I, III, IV, laminine) in comparison with five keloids.
  • The clinical diagnosis was BCC (13), squamous cell carcinoma (one) or keloid (one).
  • Fourteen lesions came from the face, nine of them from the ear.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Collagen. Keloid / pathology. Skin Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18795924.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 9007-34-5 / Collagen
  •  go-up   go-down


45. Essers B, Nieman F, Prins M, Smeets N, Neumann H: Perceptions of facial aesthetics in surgical patients with basal cell carcinoma. J Eur Acad Dermatol Venereol; 2007 Oct;21(9):1209-14
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Perceptions of facial aesthetics in surgical patients with basal cell carcinoma.
  • BACKGROUND: Basal cell carcinoma (BCC) is a non-melanoma form of skin cancer that is frequently localized within the cervicofacial area.
  • [MeSH-major] Carcinoma, Basal Cell / psychology. Esthetics. Face. Skin Neoplasms / psychology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17894707.001).
  • [ISSN] 0926-9959
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] Netherlands
  •  go-up   go-down


46. Neale RE, Davis M, Pandeya N, Whiteman DC, Green AC: Basal cell carcinoma on the trunk is associated with excessive sun exposure. J Am Acad Dermatol; 2007 Mar;56(3):380-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma on the trunk is associated with excessive sun exposure.
  • BACKGROUND AND OBJECTIVE: Basal cell carcinoma (BCC) is the most common of all cancers.
  • METHODS: The study was set in the context of the Nambour Skin Cancer Study, a community-based follow-up study among 1621 participants with virtually complete ascertainment of BCCs between 1992 and 2004.
  • We compared phenotypic and sun exposure characteristics of participants who developed a first BCC of the head or trunk with those of participants who had no diagnosis of BCC.
  • CONCLUSIONS: BCCs of the trunk are the result of overexposure of the sensitive basal cells of the epidermis to ultraviolet radiation.
  • This may result from acute intense exposures sufficient to cause sunburn among people whose ability to tan makes the skin of their face generally less susceptible to the carcinogenic effects of ultraviolet radiation.
  • [MeSH-major] Carcinoma, Basal Cell / etiology. Environmental Exposure. Neoplasms, Radiation-Induced. Skin Neoplasms / etiology. Sunlight / adverse effects

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17097387.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


47. Ziefle S, Schüle D, Breuninger H, Schippert W, Moehrle M: Confocal laser scanning microscopy vs 3-dimensional histologic imaging in basal cell carcinoma. Arch Dermatol; 2010 Aug;146(8):843-7
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Confocal laser scanning microscopy vs 3-dimensional histologic imaging in basal cell carcinoma.
  • OBJECTIVE: To compare ex vivo confocal laser scanning microscopy (CLSM), which offers rapid images without the need for tissue processing, vs 3-dimensional histologic imaging, the criterion standard treatment for basal cell carcinomas in high-risk areas of the face.
  • Patients Seventy-two consecutive surgically removed basal cell carcinomas were examined using CLSM vs standard paraffin-embedded 3-dimensional histologic imaging.
  • MAIN OUTCOME MEASURES: Diagnostic accuracy of ex vivo CLSM to detect tumor strands of basal cell carcinomas and the practicality of using CLSM vs 3-dimensional histologic slides in micrographic surgery.
  • CONCLUSIONS: Confocal laser scanning microscopy lacks high sensitivity to detect small tumor strands of basal cell carcinomas.
  • [MeSH-major] Carcinoma, Basal Cell / diagnosis. Microscopy, Confocal / methods. Skin Neoplasms / diagnosis
  • [MeSH-minor] Face / pathology. Hospitals, University. Humans. Imaging, Three-Dimensional / methods. Mohs Surgery / methods. Paraffin Embedding. Prospective Studies. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Arch Dermatol. 2010 Aug;146(8):909-10 [20713827.001]
  • (PMID = 20713814.001).
  • [ISSN] 1538-3652
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


48. Richmond-Sinclair NM, Pandeya N, Ware RS, Neale RE, Williams GM, van der Pols JC, Green AC: Incidence of basal cell carcinoma multiplicity and detailed anatomic distribution: longitudinal study of an Australian population. J Invest Dermatol; 2009 Feb;129(2):323-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence of basal cell carcinoma multiplicity and detailed anatomic distribution: longitudinal study of an Australian population.
  • A proportion of individuals are affected multiple times by basal cell carcinoma (BCC), but the rate and extent to which this occurs is unknown.
  • Between 1997 and 2006, 663 BCCs were confirmed in 301 of 1,337 participants in the population-based Nambour Skin Cancer Study.
  • [MeSH-major] Carcinoma, Basal Cell / epidemiology. Carcinoma, Basal Cell / pathology. Face / pathology. Skin Neoplasms / epidemiology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18668137.001).
  • [ISSN] 1523-1747
  • [Journal-full-title] The Journal of investigative dermatology
  • [ISO-abbreviation] J. Invest. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


49. Vinciullo C, Elliott T, Francis D, Gebauer K, Spelman L, Nguyen R, Weightman W, Sheridan A, Reid C, Czarnecki D, Murrell D: Photodynamic therapy with topical methyl aminolaevulinate for 'difficult-to-treat' basal cell carcinoma. Br J Dermatol; 2005 Apr;152(4):765-72
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy with topical methyl aminolaevulinate for 'difficult-to-treat' basal cell carcinoma.
  • BACKGROUND: Basal cell carcinoma (BCC) may be difficult to treat by conventional means, particularly if the lesions are large or located in the mid-face (H-zone).
  • [MeSH-major] Aminolevulinic Acid / administration & dosage. Aminolevulinic Acid / analogs & derivatives. Carcinoma, Basal Cell / drug therapy. Photochemotherapy / methods. Photosensitizing Agents / administration & dosage. Skin Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15840111.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / methyl 5-aminolevulinate; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


50. Bøgelund FS, Philipsen PA, Gniadecki R: Factors affecting the recurrence rate of basal cell carcinoma. Acta Derm Venereol; 2007;87(4):330-4
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Factors affecting the recurrence rate of basal cell carcinoma.
  • The aim of this retrospective survey was to determine recurrence rates after treatment of basal cell carcinomas in a single academic dermatology department.
  • A total of 1016 patients with 1593 histologically verified basal cell carcinomas (n=1212 primary and n=381 relapsing) were included.
  • The relapse rate for primary basal cell carcinomas on the scalp was highest (odds ratio (OR)=2.8, 95% confidence interval (CI) 1.5-5.3).
  • T2 and T3 tumours showed a 2- and 3-fold increased relapse rate, respectively, compared with T1 basal cell carcinomas.
  • Patients with chronic skin diseases had a 50% lower risk of relapse than healthy patients (OR=0.5, CI=0.3-0.8).
  • Recurrent basal cell carcinomas had a higher relapse rate than primary lesions (OR=1.8, CI=1.4-2.2).
  • Patients treated in a specialized skin cancer unit had a 6.4-fold (CI=2.4-17.4) higher cure rate compared with those treated by less experienced physicians.
  • Treatment in the setting of a specialized skin cancer unit yields a much lower relapse rate.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Neoplasm Recurrence, Local / epidemiology. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Clinical Competence. Curettage. Denmark / epidemiology. Dermatology. Face. Female. Hospital Units. Humans. Male. Middle Aged. Photochemotherapy. Retrospective Studies. Scalp

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17598036.001).
  • [ISSN] 0001-5555
  • [Journal-full-title] Acta dermato-venereologica
  • [ISO-abbreviation] Acta Derm. Venereol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Sweden
  •  go-up   go-down


51. Wiedemeyer K, Hartschuh W: Trichoblastomas with Merkel cell proliferation in nevi sebacei in Schimmelpenning-Feuerstein-Mims syndrome--histological differentiation between trichoblastomas and basal cell carcinomas. J Dtsch Dermatol Ges; 2009 Jul;7(7):612-5
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trichoblastomas with Merkel cell proliferation in nevi sebacei in Schimmelpenning-Feuerstein-Mims syndrome--histological differentiation between trichoblastomas and basal cell carcinomas.
  • The hallmark of Schimmelpenning-Feuerstein-Mims syndrome (SFMS) is a systematized nevus sebaceous that follows Blaschko lines and usually involves the face.
  • It represents a rare congenital nevus syndrome with alterations of skin, bones, CNS, eyes and heart.
  • Nevi sebacei can proliferate and develop into epithelial tumors like trichoblastoma, syringocystadenoma and basal cell carcinoma.
  • The histological differentiation between basal cell carcinoma and trichoblastoma is difficult.
  • We present an adult woman with SFMS who was followed by multiple specialties since birth without the correct diagnosis being made.
  • She was referred to us with the diagnosis of multiple basal cell carcinomas of head and face.
  • Our diagnosis of systematized nevus sebaceus was crucial for the correct classification of SFMS.
  • We identified multiple trichoblastomas in the nevi sebacei and could exclude basal cell carcinomas.
  • [MeSH-major] Carcinoma, Merkel Cell / pathology. Merkel Cells / pathology. Nevus, Sebaceous of Jadassohn / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Carcinoma, Basal Cell / pathology. Cell Proliferation. Diagnosis, Differential. Female. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19192012.001).
  • [ISSN] 1610-0387
  • [Journal-full-title] Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
  • [ISO-abbreviation] J Dtsch Dermatol Ges
  • [Language] eng; ger
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


52. Leonardi R, Licciardello V, Santarelli A, Ciavarella D, Bolouri S, Härle F, Caltabiano M, Lo Muzio L: Nevoid Basal cell carcinoma syndrome: a cephalometric study of patients and controls. J Craniofac Surg; 2009 Jan;20(1):203-8
Genetic Alliance. consumer health - Nevoid basal cell carcinoma syndrome.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nevoid Basal cell carcinoma syndrome: a cephalometric study of patients and controls.
  • Craniofacial morphology of patients with nevoid basal cell carcinoma syndrome (NBCCS) has sometimes been reported at clinical examination, but any investigation has described it on the basis of cephalometric measurements.The purpose of this study was to conduct a cephalometric analysis of patients with NBCCS and to compare measurements with non-NBCCS subjects of similar ages, to elucidate if there is any relationship between NBCCS and craniofacial morphology.The study population consisted of 14 adult patients (9 men and 5 women), ranging in age from 18.2 to 56.8 years, with the diagnosis of NBCCS, with good-quality lateral cephalometric radiographs, and 14 adult healthy patients matched for age and sex to the NBCCS group.
  • On the contrary, the facial convexity (P <or= 0.0189) and the mandibular arc angle (P <or= 0.0378) were reduced in NBCCS subjects.According to these findings, NBCCS patients presented a sagittal lengthening of the anterior cranial base and maxilla and a vertically and horizontally overdeveloped mandible, together with the features of a long-face syndrome with a large gonial angle.
  • [MeSH-major] Basal Cell Nevus Syndrome / pathology. Cephalometry / methods. Face. Facial Bones / pathology. Skull / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19165028.001).
  • [ISSN] 1536-3732
  • [Journal-full-title] The Journal of craniofacial surgery
  • [ISO-abbreviation] J Craniofac Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. Mueller CK, Nicolaus K, Thorwarth M, Schultze-Mosgau S: Multivariate analysis of the influence of patient-, tumor-, and management-related factors on the outcome of surgical therapy for facial basal-cell carcinoma. Oral Maxillofac Surg; 2010 Sep;14(3):163-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multivariate analysis of the influence of patient-, tumor-, and management-related factors on the outcome of surgical therapy for facial basal-cell carcinoma.
  • PURPOSE: This retrospective, case-control study aimed at evaluating the influence of patient-, tumor-, and management-related factors on the outcome of surgical therapy for facial basal-cell carcinoma (BCC) employing a multivariate analysis.
  • METHODS: One hundred one patients who underwent ablative surgery for BCC of the face at the Department of Oral and Maxillofacial Surgery/ Plastic Surgery, University Hospital Jena, between April 2005 and January 2009, were analyzed.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Facial Neoplasms / surgery. Skin Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Jan 1;64(1):280-8 [16377416.001]
  • [Cites] Dermatol Surg. 2009 Sep;35(9):1349-54 [19500127.001]
  • [Cites] Int J Oral Maxillofac Surg. 2009 Nov;38(11):1194-200 [19716681.001]
  • [Cites] N Engl J Med. 2005 Nov 24;353(21):2262-9 [16306523.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Nov 1;57(3):803-12 [14529787.001]
  • [Cites] Eur J Orthod. 2006 Jun;28(3):274-81 [16415084.001]
  • [Cites] Skin Res Technol. 2009 Aug;15(3):357-63 [19624433.001]
  • [Cites] J Oral Maxillofac Surg. 1996 Mar;54(3):297-302; discussion 302-3 [8600236.001]
  • [Cites] Br J Dermatol. 2008 Jul;159(1):35-48 [18593385.001]
  • [Cites] Br J Plast Surg. 2002 Jun;55(4):293-7 [12160534.001]
  • [Cites] Coll Antropol. 2007 Jan;31 Suppl 1:91-6 [17469760.001]
  • [Cites] Quintessence Int. 2005 Nov-Dec;36(10):759-69 [16261792.001]
  • [Cites] Br J Plast Surg. 2002 Dec;55(8):616-22 [12550113.001]
  • [Cites] Arch Facial Plast Surg. 2007 Sep-Oct;9(5):344-51 [17875828.001]
  • [Cites] J Dtsch Dermatol Ges. 2009 Dec;7(12):1075-82; quiz 1083 [19456852.001]
  • [Cites] Radiother Oncol. 2009 Dec;93(3):581-5 [19733409.001]
  • [Cites] Plast Reconstr Surg. 2004 Jun;113(7):2006-11 [15253190.001]
  • [Cites] J Invest Dermatol. 2004 Oct;123(4):634-8 [15373766.001]
  • [Cites] J Am Acad Dermatol. 2001 Feb;44(2):224-30 [11174379.001]
  • [Cites] Lancet. 2004 Nov 13-19;364(9447):1766-72 [15541449.001]
  • [Cites] Lancet Oncol. 2008 Dec;9(12):1149-56 [19010733.001]
  • [Cites] J Surg Res. 2010 May 15;160(2):340-8 [19394654.001]
  • (PMID = 20349095.001).
  • [ISSN] 1865-1569
  • [Journal-full-title] Oral and maxillofacial surgery
  • [ISO-abbreviation] Oral Maxillofac Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


54. Sedda AF, Rossi G, Cipriani C, Carrozzo AM, Donati P: Dermatological high-dose-rate brachytherapy for the treatment of basal and squamous cell carcinoma. Clin Exp Dermatol; 2008 Nov;33(6):745-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dermatological high-dose-rate brachytherapy for the treatment of basal and squamous cell carcinoma.
  • BACKGROUND: Basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) are among the most common cancers in humans.
  • METHODS: In total, 53 patients with histologically confirmed diagnosis of BCC and of SCC were enrolled for the treatment.
  • [MeSH-major] Brachytherapy / methods. Carcinoma, Basal Cell / radiotherapy. Carcinoma, Squamous Cell / radiotherapy. Facial Neoplasms / radiotherapy. Neoplasm Recurrence, Local / radiotherapy. Skin Neoplasms / radiotherapy
  • [MeSH-minor] Beta Particles / therapeutic use. Face. Female. Follow-Up Studies. Humans. Male. Nose Neoplasms / radiotherapy. Ointments. Radiotherapy Dosage. Remission Induction. Rhenium / therapeutic use

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18681873.001).
  • [ISSN] 1365-2230
  • [Journal-full-title] Clinical and experimental dermatology
  • [ISO-abbreviation] Clin. Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Ointments; 7440-15-5 / Rhenium
  •  go-up   go-down


55. Kamalpour L, Gammon B, Larsen F, Cashman R, Cockerell C: A finding of granuloma faciale associated with basal cell carcinoma. J Cutan Pathol; 2009 Oct;36(10):1103-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A finding of granuloma faciale associated with basal cell carcinoma.
  • The clinical differential diagnosis of violaceous plaques on the face is broad and includes both neoplasms and inflammatory dermatoses.
  • We report the first case of a basal cell carcinoma (BCC) superficial to an underlying granuloma faciale (GF).
  • Histological examination of a skin biopsy from the cheek revealed superficial BCC and GF.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Facial Dermatoses / pathology. Facial Neoplasms / pathology. Granuloma / pathology
  • [MeSH-minor] Diagnosis, Differential. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 John Wiley & Sons A/S.
  • (PMID = 19602064.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


56. Rodriguez-Vigil T, Vázquez-López F, Perez-Oliva N: Recurrence rates of primary basal cell carcinoma in facial risk areas treated with curettage and electrodesiccation. J Am Acad Dermatol; 2007 Jan;56(1):91-5
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrence rates of primary basal cell carcinoma in facial risk areas treated with curettage and electrodesiccation.
  • BACKGROUND: The incidence of basal cell carcinoma (BCC) is increasing.
  • The primary outcome was recurrence of carcinoma, which was clinically evaluated by at least two observers in consensus.
  • RESULTS: The 5-year cumulative non-RR in the best-case scenario was 98.80% (SE 0.70, 95% confidence interval 97.40%-100%); thus, a 5-year cumulative RR of 1.20% was found after CE in our medium- and high-risk BCCs of the face (best case).
  • CONCLUSION: High 5-year cure rates can be obtained after CE of primary, nonfibrosing BCCs of medium- and high-risk areas of the face performed in a specialized section.
  • [MeSH-major] Carcinoma, Basal Cell / epidemiology. Curettage. Electrocoagulation. Facial Neoplasms / epidemiology. Neoplasm Recurrence, Local / epidemiology. Skin Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17190625.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


57. Ericson MB, Uhre J, Strandeberg C, Stenquist B, Larkö O, Wennberg AM, Rosén A: Bispectral fluorescence imaging combined with texture analysis and linear discrimination for correlation with histopathologic extent of basal cell carcinoma. J Biomed Opt; 2005 May-Jun;10(3):034009
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bispectral fluorescence imaging combined with texture analysis and linear discrimination for correlation with histopathologic extent of basal cell carcinoma.
  • Fluorescence imaging has been shown to be a potential complement to visual inspection for demarcation of basal cell carcinoma (BCC), which is the most common type of skin cancer.
  • In this work, we have tried to further improve the ability of this technique to discriminate between areas of tumor and normal skin by implementing texture analysis and Fisher linear discrimination (FLD) on bispectral fluorescence data of BCCs located on the face.
  • [MeSH-major] Algorithms. Artificial Intelligence. Carcinoma, Basal Cell / pathology. Image Interpretation, Computer-Assisted / methods. Microscopy, Fluorescence / methods. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2005 Society of Photo-Optical Instrumentation Engineers.
  • (PMID = 16229653.001).
  • [ISSN] 1083-3668
  • [Journal-full-title] Journal of biomedical optics
  • [ISO-abbreviation] J Biomed Opt
  • [Language] eng
  • [Publication-type] Clinical Trial; Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


58. Kuijpers DI, Thissen MR, Berretty PJ, Ideler FH, Nelemans PJ, Neumann MH: Surgical excision versus curettage plus cryosurgery in the treatment of basal cell carcinoma. Dermatol Surg; 2007 May;33(5):579-87
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical excision versus curettage plus cryosurgery in the treatment of basal cell carcinoma.
  • BACKGROUND: Both cryosurgery, with and without prior curettage, and surgical excision (SE) are common therapeutic strategies for basal cell carcinoma (BCC).
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Neoplasm Recurrence, Local / surgery. Skin Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cryosurgery / methods. Curettage / methods. Disease-Free Survival. Face. Female. Humans. Male. Middle Aged. Netherlands. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Dermatol Surg. 2008 Apr;34(4):582 [18248484.001]
  • (PMID = 17451581.001).
  • [ISSN] 1076-0512
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  •  go-up   go-down


59. Friedrich RE, Giese M, Li L, Schenk Y, Schmelzle R: Diagnosis, treatment and follow-up control in 124 patients with basal cell carcinoma of the maxillofacial region treated from 1992 to 1997. Anticancer Res; 2005 May-Jun;25(3A):1693-7
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis, treatment and follow-up control in 124 patients with basal cell carcinoma of the maxillofacial region treated from 1992 to 1997.
  • AIM: The aim of this study was to analyze diagnostic and therapeutic procedures and the outcome of patients treated for the most common malignant tumor of the facial skin, basal cell carcinoma.
  • PATIENTS AND METHODS: The files of patients with basal cell carcinoma (BCC) treated over a period of 6 years were evaluated.
  • RESULTS: One-hundred and twenty-four patients were treated for 216 basal cell carcinomas (solitary: 67%, multiple: 33%).
  • The tumors were predominantly located in the skin covering the middle third of the face.
  • CONCLUSION: Basal cell carcinoma is a malignant tumor, slowly growing and often showing wide extension to macroscopically non-affected sites.
  • [MeSH-major] Carcinoma, Basal Cell / diagnosis. Carcinoma, Basal Cell / therapy. Face / pathology. Jaw / pathology. Skin Neoplasms / diagnosis. Skin Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16033084.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


60. Kuzmina N, Talme T, Lapins J, Emtestam L: Non-invasive preoperative assessment of basal cell carcinoma of nodular and superficial types. Skin Res Technol; 2005 Aug;11(3):196-200
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-invasive preoperative assessment of basal cell carcinoma of nodular and superficial types.
  • BACKGROUND/AIMS: Although various biophysical properties can be used to distinguish basal cell carcinoma (BCC) tissue from normal skin, none permits typing of the tumour.
  • Measurements were also made in healthy skin on the contralateral side as reference.
  • The diagnosis was confirmed by histological examination.
  • Since most of the NBCC were located on the face and most SBCC on the trunk, their baseline impedance characteristics (i.e., impedance indices magnitude index (MIX) and imaginary part index (IMIX)) differed significantly.
  • CONCLUSIONS: As with LD and TEWL, definite differences in IMP were detected between healthy skin and BCC lesions.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Skin Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15998331.001).
  • [ISSN] 0909-752X
  • [Journal-full-title] Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI)
  • [ISO-abbreviation] Skin Res Technol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  •  go-up   go-down


61. Bobadilla F, Wortsman X, Muñoz C, Segovia L, Espinoza M, Jemec GB: Pre-surgical high resolution ultrasound of facial basal cell carcinoma: correlation with histology. Cancer Imaging; 2008;8:163-72
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pre-surgical high resolution ultrasound of facial basal cell carcinoma: correlation with histology.
  • The aim of this study was to analyze the scope of pre-surgical high resolution ultrasound in basal cell carcinoma (BCC).
  • BCC is the most common human cancer.
  • Pre-operative imaging may aid surgical planning by identifying the extent and location of a neoplasm, which can be interesting at zones with higher risk of recurrences such as the face.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Carcinoma, Basal Cell / ultrasonography. Skin Neoplasms / pathology. Skin Neoplasms / ultrasonography. Ultrasonography, Doppler, Color
  • [MeSH-minor] Aged. Aged, 80 and over. Analysis of Variance. Biopsy, Needle. Cohort Studies. Face / pathology. Face / ultrasonography. Female. Follow-Up Studies. Humans. Immunohistochemistry. Male. Middle Aged. Mohs Surgery / methods. Preoperative Care / methods. Probability. Risk Assessment. Sensitivity and Specificity. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Dermatol. 2000 Aug;10(6):492-7 [10980479.001]
  • [Cites] J Cancer Res Ther. 2006 Jul-Sep;2(3):140-3 [17998694.001]
  • [Cites] Ann Plast Surg. 2001 Feb;46(2):192-3 [11216624.001]
  • [Cites] J Radiol. 2001 May;82(5):563-71 [11416794.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2003 Mar;17(2):167-70 [12705745.001]
  • [Cites] BMJ. 2003 Oct 4;327(7418):794-8 [14525881.001]
  • [Cites] Clin Exp Dermatol. 2003 Nov;28(6):632-8 [14616832.001]
  • [Cites] Skin Res Technol. 2004 Feb;10(1):23-31 [14731245.001]
  • [Cites] Dermatol Surg. 2004 Feb;30(2 Pt 2):301-10 [14871225.001]
  • [Cites] Acta Derm Venereol. 2004;84(1):44-7 [15040477.001]
  • [Cites] J Biomed Opt. 2004 Mar-Apr;9(2):292-8 [15065894.001]
  • [Cites] J Am Acad Dermatol. 1990 Mar;22(3):413-7 [2312827.001]
  • [Cites] J Am Acad Dermatol. 1991 Jan;24(1):1-13 [1999506.001]
  • [Cites] Radiology. 1993 Oct;189(1):69-76 [8372222.001]
  • [Cites] Cutis. 1994 Jan;53(1):44-8 [8119078.001]
  • [Cites] Dermatol Surg. 1996 Feb;22(2):131-6 [8608374.001]
  • [Cites] Radiographics. 1997 Nov-Dec;17(6):1559-65 [9397463.001]
  • [Cites] Eur J Radiol. 1998 May;27 Suppl 2:S215-23 [9652525.001]
  • [Cites] Ophthalmologica. 1998;212 Suppl 1:40-1 [9730747.001]
  • [Cites] Ann Dermatol Venereol. 1998 Aug;125(8):500-4 [9747315.001]
  • [Cites] Br J Plast Surg. 1999 Jan;52(1):24-8 [10343586.001]
  • [Cites] Arch Dermatol. 1999 Oct;135(10):1177-83 [10522664.001]
  • [Cites] Arch Dermatol. 2005 Feb;141(2):217-24 [15724019.001]
  • [Cites] Arch Dermatol. 2006 Feb;142(2):187-94 [16490846.001]
  • [Cites] Otolaryngol Head Neck Surg. 2006 Mar;134(3):471-5 [16500447.001]
  • [Cites] Radiol Med. 2006 Aug;111(5):702-8 [16791462.001]
  • [Cites] Eur J Dermatol. 2006 Sep-Oct;16(5):543-7 [17101476.001]
  • [Cites] J Radiol. 2006 Dec;87(12 Pt 2):1946-61 [17211309.001]
  • [Cites] Bull Cancer. 2007 Jan;94(1):93-8 [17237009.001]
  • [Cites] J Cutan Med Surg. 2006 May-Jun;10(3):122-7 [17241587.001]
  • [Cites] Acta Derm Venereol. 2007;87(4):330-4 [17598036.001]
  • [Cites] Plast Reconstr Surg. 2007 Oct;120(5):1240-8 [17898596.001]
  • [Cites] Dermatol Surg. 2007 Oct;33(10):1158-74 [17903149.001]
  • [Cites] Dermatol Surg. 2007 Oct;33(10):1207-14 [17903153.001]
  • [Cites] Dermatol Surg. 2007 Oct;33(10):1215-9 [17903154.001]
  • [Cites] Dermatol Surg. 2007 Oct;33(10):1220-7; discussion 1226-7 [17903155.001]
  • [Cites] Dermatol Surg. 2007 Nov;33(11):1340-2 [17958586.001]
  • [Cites] Br J Plast Surg. 2000 Oct;53(7):563-6 [11000071.001]
  • (PMID = 18812268.001).
  • [ISSN] 1470-7330
  • [Journal-full-title] Cancer imaging : the official publication of the International Cancer Imaging Society
  • [ISO-abbreviation] Cancer Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2556504
  •  go-up   go-down


62. Jacyk WK, Rütten A, Requena L: Fibrous papule of the face with granular cells. Dermatology; 2008;216(1):56-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fibrous papule of the face with granular cells.
  • Fibrous papule of the face is a common benign lesion located most often on the nose.
  • It presents usually as a single small, firm, skin-coloured papule and is often misdiagnosed as melanocytic naevus, wart or small nodular basal cell carcinoma.
  • Uncommon histopathologic variants of fibrous papule of the face include hypercellular, clear-cell, pleomorphic, pigmented, inflammatory and granular-cell types.
  • We present here a patient with the syndrome of familial cancer and fibrous papule of the face with granular cells.
  • In our patient the mutations in the 2 most often affected DNA mismatch repair genes of Muir-Torre syndrome were not found, therefore the origin of the familial cancer syndrome remains unknown.
  • Probably the occurrence of the granular-cell fibrous papule of the face was coincidental.
  • [MeSH-major] Angiofibroma / pathology. Facial Neoplasms / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 S. Karger AG, Basel.
  • [CommentIn] Dermatology. 2008;217(1):56-7; author reply 57 [18382105.001]
  • (PMID = 18032900.001).
  • [ISSN] 1421-9832
  • [Journal-full-title] Dermatology (Basel, Switzerland)
  • [ISO-abbreviation] Dermatology (Basel)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


63. Toth J, Lukats O, Pecorella I: Cbfa1/Runx2 expression in an ossifying basal cell carcinoma of the eyelid. Arch Dermatol Res; 2010 Nov;302(9):695-700

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cbfa1/Runx2 expression in an ossifying basal cell carcinoma of the eyelid.
  • A case of basal cell carcinoma (BCC) with intratumoural bone formation affecting the eyelid of a 77-year-old lady is described.
  • We revised the 23 cases described in the literature: most of them occurred on the face.
  • [MeSH-major] Antigens, Differentiation / metabolism. Carcinoma, Basal Cell / metabolism. Core Binding Factor Alpha 1 Subunit / metabolism. Eyelid Neoplasms / metabolism. Osteoblasts / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Arch Dermatol Res. 2013 Jul;305(5):461. Jeannette, Toth [corrected to Toth, Jeannette]; Olga, Lukats [corrected to Lukats, Olga]; Irene, Pecorella [corrected to Pecorella, Irene]
  • (PMID = 20658243.001).
  • [ISSN] 1432-069X
  • [Journal-full-title] Archives of dermatological research
  • [ISO-abbreviation] Arch. Dermatol. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, Differentiation; 0 / Core Binding Factor Alpha 1 Subunit
  •  go-up   go-down


64. Galletly NP, McGinty J, Dunsby C, Teixeira F, Requejo-Isidro J, Munro I, Elson DS, Neil MA, Chu AC, French PM, Stamp GW: Fluorescence lifetime imaging distinguishes basal cell carcinoma from surrounding uninvolved skin. Br J Dermatol; 2008 Jul;159(1):152-61
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fluorescence lifetime imaging distinguishes basal cell carcinoma from surrounding uninvolved skin.
  • OBJECTIVES: To establish whether FLIM of skin autofluorescence can provide useful contrast between basal cell carcinomas (BCCs) and surrounding uninvolved skin.
  • METHODS: Unstained excision biopsies of 25 BCCs were imaged en face with FLIM following excitation of autofluorescence with a 355 nm pulsed ultraviolet laser.
  • RESULTS: Using FLIM we were able to distinguish areas of BCC from surrounding skin in an ex vivo study.
  • Significant reductions in mean fluorescence lifetimes between areas of BCC and areas of surrounding uninvolved skin were demonstrated (P < 0.0001).
  • Moreover, wide-field false-colour images of fluorescence lifetimes clearly discriminated areas of BCC from the surrounding uninvolved skin.
  • [MeSH-major] Carcinoma, Basal Cell / diagnosis. Diagnostic Imaging / methods. Skin Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Diagnostic Imaging.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18460029.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


65. Caekelbergh K, Nikkels AF, Leroy B, Verhaeghe E, Lamotte M, Vincent R: Photodynamic therapy using methyl aminolevulinate in the management of primary superficial basal cell carcinoma: clinical and health economic outcomes. J Drugs Dermatol; 2009 Nov;8(11):992-6
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy using methyl aminolevulinate in the management of primary superficial basal cell carcinoma: clinical and health economic outcomes.
  • BACKGROUND: Basal cell carcinoma (BCC) is the most common form of skin cancer worldwide.
  • The mean number of lesions per patient was 1.6, mostly located on the face, the back and the chest.
  • [MeSH-major] Aminolevulinic Acid / analogs & derivatives. Carcinoma, Basal Cell / drug therapy. Photochemotherapy / methods. Photosensitizing Agents / therapeutic use. Skin Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19894366.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / methyl 5-aminolevulinate; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


66. Fattah A, Pollock J, Maheshwar A, Britto JA: Big Bad BCCs: craniofacial resection and reconstruction for atypical basal cell carcinomata. J Plast Reconstr Aesthet Surg; 2010 May;63(5):e433-41
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Big Bad BCCs: craniofacial resection and reconstruction for atypical basal cell carcinomata.
  • Basal cell carcinoma (BCC) is the most common malignancy of the body and most frequently occurs in the head and neck.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Face / surgery. Head and Neck Neoplasms / surgery. Reconstructive Surgical Procedures / methods. Scalp. Skin Neoplasms / surgery. Skull / surgery

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 British Association of Plastic, Reconstructive and Aesthetic Surgeons. Published by Elsevier Ltd. All rights reserved.
  • (PMID = 19879202.001).
  • [ISSN] 1878-0539
  • [Journal-full-title] Journal of plastic, reconstructive & aesthetic surgery : JPRAS
  • [ISO-abbreviation] J Plast Reconstr Aesthet Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


67. Downs N, Parisi A: Measurements of the anatomical distribution of erythemal ultraviolet: a study comparing exposure distribution to the site incidence of solar keratoses, basal cell carcinoma and squamous cell carcinoma. Photochem Photobiol Sci; 2009 Aug;8(8):1195-201
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Measurements of the anatomical distribution of erythemal ultraviolet: a study comparing exposure distribution to the site incidence of solar keratoses, basal cell carcinoma and squamous cell carcinoma.
  • The UV exposures were compared with existing data detailing the anatomical distribution of basal cell carcinoma (BCC), squamous cell carcinoma (SCC) and solar keratoses (SK).
  • Surface UV exposures to unprotected skin surfaces have been presented for each of the face, neck, arm, hand and leg assessing a total of 1453 body sites (2491 measurements).
  • The median anatomical UV expressed relative to the horizontal plane ambient UV for each of the face, neck, forearm, hand and leg regions of the body varied from 26%, 23%, 13%, 30% and 12% respectively in the 0 degrees-30 degrees SZA range; 39%, 36%, 17%, 35% and 23% in the 30 degrees-50 degrees SZA range; and 48%, 59%, 41%, 42% and 47% in the 50 degrees-80 degrees SZA range.
  • Detailed positions of UV exposure measured over the face, neck, arm, hand and leg were more closely related to NMSC incidence data for the face and upper limbs.
  • [MeSH-major] Carcinoma, Basal Cell / epidemiology. Carcinoma, Squamous Cell / epidemiology. Keratosis / epidemiology. Skin / pathology. Ultraviolet Rays
  • [MeSH-minor] Arm / pathology. Arm / radiation effects. Australia / epidemiology. Dose-Response Relationship, Radiation. Environmental Exposure. Face / pathology. Face / radiation effects. Hand / pathology. Hand / radiation effects. Humans. Incidence. Leg / pathology. Leg / radiation effects. Neck / pathology. Neck / radiation effects

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19639123.001).
  • [ISSN] 1474-905X
  • [Journal-full-title] Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology
  • [ISO-abbreviation] Photochem. Photobiol. Sci.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


68. Vereecken P, Da Costa CM, Steels E, De Lathouwer O, Heenen M, De Mey A: Fluorescence diagnosis of face-located basal cell carcinomas: a new dermatological procedure which may help the surgeon. Acta Chir Belg; 2007 Mar-Apr;107(2):205-7
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fluorescence diagnosis of face-located basal cell carcinomas: a new dermatological procedure which may help the surgeon.
  • Cutaneous Fluorescence Diagnosis (FD) is a new promising dermatological procedure which is based on the combination of a local application of a photosensitizer such as 5-aminolevulinic acid (ALA) or its methyl ester (MAL) and the use of a light source (red light) adapted to the absorption spectrum of these molecules.
  • The targeted photosensitization of skin cancers, particularily superficial and extensive lesions including superficial basal cell carcinoma and Bowen's disease, by ALA or MAL induced porphyrins leads to a selective red fluorescence which can be demonstrated by Wood's lamp.
  • [MeSH-major] Carcinoma, Basal Cell / diagnosis. Carcinoma, Basal Cell / therapy. Fluorescence. Skin Neoplasms / diagnosis. Skin Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17515272.001).
  • [ISSN] 0001-5458
  • [Journal-full-title] Acta chirurgica Belgica
  • [ISO-abbreviation] Acta Chir. Belg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Belgium
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / Porphyrins; 0 / methyl 5-aminolevulinate; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


69. Ntomouchtsis A, Vahtsevanos K, Patrikidou A, Andreadis C, Tsobanidou C, Antoniades K: Adnexal skin carcinomas of the face. J Craniofac Surg; 2009 Jan;20(1):134-7
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adnexal skin carcinomas of the face.
  • Skin adnexal neoplasms are rare tumors, and knowledge on their exact histological development and pathogenesis remains fragmented.
  • Their diagnosis and management are frequently troublesome, especially for malignant tumors.
  • We present a retrospective case series of malignant appendageal tumors of the face.
  • Records of patients with histologically confirmed adnexal skin carcinoma managed at a single department during the period 1995 to 2004 were reviewed.
  • Clinical and histological features, tumor biological behavior, diagnostic difficulties, and recommended management are discussed.In conclusion, adnexal skin tumors should be considered in the differential diagnosis of skin tumors, particularly in view of their more sinister prognosis compared with other nonmelanoma skin tumors.
  • [MeSH-major] Carcinoma, Skin Appendage / surgery. Facial Neoplasms / surgery. Skin Neoplasms / surgery
  • [MeSH-minor] Aged. Aged, 80 and over. Carcinoma, Basal Cell / diagnosis. Carcinoma, Squamous Cell / diagnosis. Cohort Studies. Diagnosis, Differential. Disease-Free Survival. Eyelid Neoplasms / surgery. Female. Follow-Up Studies. Humans. Lymphatic Metastasis / pathology. Male. Middle Aged. Neck Dissection. Neoplasm Recurrence, Local / pathology. Neoplasms, Second Primary / pathology. Nose Neoplasms / surgery. Retrospective Studies. Surgical Flaps. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19165010.001).
  • [ISSN] 1536-3732
  • [Journal-full-title] The Journal of craniofacial surgery
  • [ISO-abbreviation] J Craniofac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


70. Rose RF, Merchant W, Stables GI, Lyon CL, Platt A: Basal cell carcinoma with a sarcomatous component (carcinosarcoma): a series of 5 cases and a review of the literature. J Am Acad Dermatol; 2008 Oct;59(4):627-32
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma with a sarcomatous component (carcinosarcoma): a series of 5 cases and a review of the literature.
  • Four lesions occurred on the face and one on the trunk.
  • Each tumor had an epithelial component resembling a typical nodular basal cell carcinoma.
  • [MeSH-major] Carcinosarcoma / pathology. Facial Neoplasms / pathology. Skin Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18793937.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 23
  •  go-up   go-down


71. Clément C, Lebreuilly I, Stephan A, De Raucourt S, Dutriaux C, Comoz F, Leroy D, Verneuil L: [Intracranial extension of cutaneous facial squamous cell carcinoma: involvement of the neurotropic pathway]. Ann Dermatol Venereol; 2010 Aug-Sep;137(8-9):551-4
Hazardous Substances Data Bank. CETUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Intracranial extension of cutaneous facial squamous cell carcinoma: involvement of the neurotropic pathway].
  • [Transliterated title] Extension intracrânienne d'un carcinome spinocellulaire de la face : implication de la voie neurotrope.
  • BACKGROUND: Squamous cell carcinoma is the most common form of skin cancer after basal cell carcinoma.
  • We report a case of late and slowly progressive recurrence of squamous cell carcinoma revealed and characterized by neurological symptoms alone.
  • OBSERVATION: A 69-year-old woman with a history of cutaneous squamous cell carcinoma on the left nostril edge removed 10 years earlier presented right trigeminal neuralgia in 2003.
  • Deep biopsy allowed a diagnosis of invasive squamous cell carcinoma to be made.
  • DISCUSSION: Neurotropism is an important feature of squamous cell carcinoma, and reveals the aggressive nature of this condition.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Facial Neoplasms / pathology. Neoplasm Invasiveness / pathology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Masson SAS. All rights reserved.
  • (PMID = 20804901.001).
  • [ISSN] 0151-9638
  • [Journal-full-title] Annales de dermatologie et de vénéréologie
  • [ISO-abbreviation] Ann Dermatol Venereol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; PQX0D8J21J / Cetuximab
  •  go-up   go-down


72. Goh BK, Ang P, Wu YJ, Goh CL: Characteristics of basal cell carcinoma amongst Asians in Singapore and a comparison between completely and incompletely excised tumors. Int J Dermatol; 2006 May;45(5):561-4
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characteristics of basal cell carcinoma amongst Asians in Singapore and a comparison between completely and incompletely excised tumors.
  • BACKGROUND: Most published series of basal cell carcinomas (BCCs) are based on Caucasian populations.
  • PATIENTS AND METHODS: A retrospective study was conducted using the case records of patients who had a primary BCC excised at the National Skin Centre between 1991 and 1995.
  • Incompletely excised BCCs were more likely than completely excised lesions to be located on the mid-face and trunk (P = 0.003), but there was no significant correlation with tumor size, tumor duration, or patient age, race, and gender.
  • Incomplete excision is associated with tumor location on the mid-face and trunk rather than tumor size or duration.
  • [MeSH-major] Carcinoma, Basal Cell / epidemiology. Neoplasm Recurrence, Local / epidemiology. Skin Neoplasms / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16700792.001).
  • [ISSN] 0011-9059
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


73. Kimyai-Asadi A, Goldberg LH, Jih MH: Accuracy of serial transverse cross-sections in detecting residual basal cell carcinoma at the surgical margins of an elliptical excision specimen. J Am Acad Dermatol; 2005 Sep;53(3):469-74
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Accuracy of serial transverse cross-sections in detecting residual basal cell carcinoma at the surgical margins of an elliptical excision specimen.
  • OBJECTIVE: Our purpose was to estimate the accuracy of serial transverse cross-sectioning (bread-loafing) at 4-mm intervals in detecting the presence of residual tumor at the margins of well-defined facial basal cell carcinomas excised as an ellipse with 2-mm surgical margins.
  • METHODS: Forty-two small (<1 cm), well-defined, primary, nonmorpheaform facial basal cell carcinomas that had been excised as an ellipse with 2-mm margins and that had positive surgical margins utilizing en-face Mohs sections were included.
  • CONCLUSION: Bread-loafing at 4-mm intervals of elliptical excision specimens from facial basal cell carcinomas excised with 2-mm surgical margins is only 44% sensitive in detecting residual tumor at the surgical margins.
  • We recommend complete histologic margin control by using en face tissue orientation (Mohs technique) to identify residual tumor and reduce the risk of tumor recurrence after elliptical excision of facial basal cell carcinomas.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Carcinoma, Basal Cell / surgery. Head and Neck Neoplasms / pathology. Head and Neck Neoplasms / surgery. Mohs Surgery. Skin Neoplasms / pathology. Skin Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16112355.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


74. Kimyai-Asadi A, Alam M, Goldberg LH, Peterson SR, Silapunt S, Jih MH: Efficacy of narrow-margin excision of well-demarcated primary facial basal cell carcinomas. J Am Acad Dermatol; 2005 Sep;53(3):464-8
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of narrow-margin excision of well-demarcated primary facial basal cell carcinomas.
  • BACKGROUND: A 4-mm surgical margin of clinically normal skin is the current standard for elliptical excision of basal cell carcinomas (BCCs).
  • However, a 4-mm surgical margin is often not feasible on the face because of cosmetic and functional concerns.
  • CONCLUSION: Narrow margins (1-3 mm) are inadequate for the excision of small, well-demarcated, primary nodular BCCs of the face.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Head and Neck Neoplasms / surgery. Mohs Surgery. Skin Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16112354.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


75. Pelucchi C, Naldi L, Di Landro A, La Vecchia C, Oncology Study Group of Italian Group for Epidemiologic Research in Dermatology: Anthropometric measures, medical history and risk of basal cell carcinoma in an Italian case-control study. Dermatology; 2008;216(3):271-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anthropometric measures, medical history and risk of basal cell carcinoma in an Italian case-control study.
  • BACKGROUND/AIMS: A few epidemiological studies investigated etiological factors for basal cell carcinoma (BCC) other than sunlight exposure and sunburns.
  • Subjects with asthma (OR = 0.26) and diabetes mellitus (OR = 0.23) showed a decreased risk of trunk BCC but not face and neck BCC.
  • CONCLUSION: The inverse relations between trunk, but not face and neck BCC, and obesity, diabetes mellitus and asthma may indirectly reflect the different role of past sunlight exposure to different body locations and variable etiologic pathways for BCCs according to body areas.
  • [MeSH-major] Body Weights and Measures. Carcinoma, Basal Cell / epidemiology. Skin Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18196938.001).
  • [ISSN] 1421-9832
  • [Journal-full-title] Dermatology (Basel, Switzerland)
  • [ISO-abbreviation] Dermatology (Basel)
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Switzerland
  • [Investigator] Betti R; Inselvini E; Crosti C; Rossi E; Pini M; Galbiati G; Ceschini R; Simonacci M; Virgili A; Lombardi A; Braga D; Puiatti P; Bonvicino A; Lo Schiavo A; Fabbrocini G; Sarracco G; Barile M; Feliciangeli M; Barba A; Cattoni D; Pestelli F; Carli P; Cusano F; Adamo F; Sclamich S; Magaton Rizzi G; Filotico R
  •  go-up   go-down


76. Rustemeyer J, Bremerich A: Outcomes after surgical treatment of facial skin basal cell carcinomas. Acta Chir Plast; 2006;48(3):89-92
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes after surgical treatment of facial skin basal cell carcinomas.
  • BACKGROUND: Missing recurrences and the aesthetic outcomes after reconstructions of the face are preoccupations in the surgical treatment of basal cell carcinomas.
  • PATIENTS: 205 patients receiving resections of basal cell carcinomas and facial skin reconstructions were included and data were analyzed.
  • Local flaps, full-thickness skin grafts and skin extension closures were carried out most often; indications for split-thickness skin grafts were rare.
  • Sensitivity disturbances occurred in only 3.6% of skin extension closures and in 11.7% of local flaps, but in 22.7% of full-thickness skin grafts and in 38.7% of split-thickness skin grafts.
  • They were classified as "unobtrusive" and "excellent or good" in 88.4% of local flaps and in 92.6% of skin extension closures, but in only 66.4% of full-thickness skin grafts and in 54% of split-thickness skin grafts.
  • CONCLUSION: Local flaps and skin extension closures provide better aesthetic and neurological outcomes after facial skin reconstructions.
  • However, skin grafts are alternative procedures for critical indications of local flaps.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Skin Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17165596.001).
  • [ISSN] 0001-5423
  • [Journal-full-title] Acta chirurgiae plasticae
  • [ISO-abbreviation] Acta Chir Plast
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down


77. Essers BA, Dirksen CD, Prins MH, Neumann HA: Assessing the public's preference for surgical treatment of primary basal cell carcinoma: a discrete-choice experiment in the south of the Netherlands. Dermatol Surg; 2010 Dec;36(12):1950-5
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessing the public's preference for surgical treatment of primary basal cell carcinoma: a discrete-choice experiment in the south of the Netherlands.
  • BACKGROUND: Basal cell carcinoma (BCC) is a slowly growing nonmelanoma type of skin cancer that often is located on the face.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Mohs Surgery. Public Opinion. Skin Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 by the American Society for Dermatologic Surgery, Inc.
  • (PMID = 21070461.001).
  • [ISSN] 1524-4725
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


78. Aigner BA, Darsow U, Grosber M, Ring J, Plötz SG: Multiple basal cell carcinomas after long-term exposure to hydrazine: case report and review of the literature. Dermatology; 2010;221(4):300-2
Hazardous Substances Data Bank. HYDRAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple basal cell carcinomas after long-term exposure to hydrazine: case report and review of the literature.
  • It is known to be a skin sensitizer, a corrosive agent and it causes dermatitis on contact.
  • The authors report the case of a 68-year-old man with multiple basal cell carcinomas (BCCs) covering his arms and face.
  • [MeSH-major] Hydrazines / toxicity. Occupational Diseases / chemically induced. Occupational Exposure. Skin Neoplasms / chemically induced
  • [MeSH-minor] Aged. Arm. Carcinoma, Basal Cell / chemically induced. Carcinoma, Basal Cell / diagnosis. Carcinoma, Basal Cell / surgery. Face. Hamartoma Syndrome, Multiple. Humans. Male

  • MedlinePlus Health Information. consumer health - Occupational Health.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. HYDRAZINE SULFATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 S. Karger AG, Basel.
  • (PMID = 21099194.001).
  • [ISSN] 1421-9832
  • [Journal-full-title] Dermatology (Basel, Switzerland)
  • [ISO-abbreviation] Dermatology (Basel)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Hydrazines; 27RFH0GB4R / hydrazine; Basal cell carcinoma, multiple
  •  go-up   go-down


79. Sharma NL, Mehta KI, Mahajan VK, Kanga AK, Sharma VC, Tegta GR: Cutaneous sporotrichosis of face: polymorphism and reactivation after intralesional triamcinolone. Indian J Dermatol Venereol Leprol; 2007 May-Jun;73(3):188-90
Hazardous Substances Data Bank. TRIAMCINOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous sporotrichosis of face: polymorphism and reactivation after intralesional triamcinolone.
  • We describe a culture-proven case of cutaneous sporotrichosis of the face mimicking lupus vulgaris initially and basal cell carcinoma later, who did not tolerate potassium iodide and failed to respond to treatment with fluconazole.

  • Genetic Alliance. consumer health - Sporotrichosis.
  • MedlinePlus Health Information. consumer health - Facial Injuries and Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17558054.001).
  • [ISSN] 0973-3922
  • [Journal-full-title] Indian journal of dermatology, venereology and leprology
  • [ISO-abbreviation] Indian J Dermatol Venereol Leprol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Antifungal Agents; 1ZK20VI6TY / Triamcinolone
  •  go-up   go-down


80. Salgarelli AC, Cangiano A, Sartorelli F, Bellini P, Collini M: The bilobed flap in skin cancer of the face: our experience on 285 cases. J Craniomaxillofac Surg; 2010 Sep;38(6):460-4
MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The bilobed flap in skin cancer of the face: our experience on 285 cases.
  • PATIENT AND METHOD: The Zitelli bilobed flap was used to treat 285 consecutive patients with basal cell carcinomas (BCCs) or squamous cell carcinomas (SCCs); 167 men (58.60%) and 118 women (41.40%) between 45 and 98 years of age.
  • CONCLUSION: In our experience the bilobed Zitelli flap for covering defects in the area of the face showed very few complications and good aesthetic results.
  • [MeSH-major] Face / surgery. Facial Neoplasms / surgery. Reconstructive Surgical Procedures / methods. Surgical Flaps
  • [MeSH-minor] Aged. Aged, 80 and over. Carcinoma, Basal Cell / surgery. Carcinoma, Squamous Cell / surgery. Female. Humans. Male. Middle Aged. Patient Satisfaction. Surveys and Questionnaires. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 European Association for Cranio-Maxillo-Facial Surgery. Published by Elsevier Ltd. All rights reserved.
  • (PMID = 19939690.001).
  • [ISSN] 1878-4119
  • [Journal-full-title] Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery
  • [ISO-abbreviation] J Craniomaxillofac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


81. Stenquist B, Ericson MB, Strandeberg C, Mölne L, Rosén A, Larkö O, Wennberg AM: Bispectral fluorescence imaging of aggressive basal cell carcinoma combined with histopathological mapping: a preliminary study indicating a possible adjunct to Mohs micrographic surgery. Br J Dermatol; 2006 Feb;154(2):305-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bispectral fluorescence imaging of aggressive basal cell carcinoma combined with histopathological mapping: a preliminary study indicating a possible adjunct to Mohs micrographic surgery.
  • BACKGROUND: Fluorescence imaging is an attractive diagnostic technique for skin tumour demarcation with potential to move to clinical use.
  • Bispectral fluorescence imaging combines skin autofluorescence with delta-aminolaevulinic acid-induced fluorescence.
  • OBJECTIVES: To investigate the agreement between bispectral fluorescence images and the histopathological tumour boundary of ill-defined basal cell carcinomas (BCCs).
  • METHODS: Twelve patients with aggressive BCC of mean diameter 16 mm (range 5-32) in the face were included in the study.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Facial Neoplasms / pathology. Mohs Surgery. Skin Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16433801.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


82. Sandberg C, Halldin CB, Ericson MB, Larkö O, Krogstad AL, Wennberg AM: Bioavailability of aminolaevulinic acid and methylaminolaevulinate in basal cell carcinomas: a perfusion study using microdialysis in vivo. Br J Dermatol; 2008 Nov;159(5):1170-6
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bioavailability of aminolaevulinic acid and methylaminolaevulinate in basal cell carcinomas: a perfusion study using microdialysis in vivo.
  • Nevertheless, the reported cure rates vary and the transdermal penetration of drugs has been discussed as a limiting factor, particularly for treatment of nodular basal cell carcinoma (BCC).
  • All lesions were located at the front of the body (head and face excluded).
  • [MeSH-major] Aminolevulinic Acid / pharmacokinetics. Carcinoma, Basal Cell / metabolism. Photosensitizing Agents / pharmacokinetics. Skin Neoplasms / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18717673.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


83. Czakó L, Tiszlavicz L, Takács R, Baradnay G, Lonovics J, Cserni G, Závodná K, Bartosova Z: [The first molecular analysis of a Hungarian HNPCC family: a novel MSH2 germline mutation]. Orv Hetil; 2005 May 15;146(20):1009-16
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Az elsó magyar hereditaer nem polypoticus colorectalis carcinoma család molekuláris vizsgálata: az MSH2 gén uj mutációja.
  • BACKGROUND: Hereditary nonpolyposis colorectal cancer is an inherited disease characterized by onset at an early age, an excess of synchronous and metachronous large bowel tumors and a variety of extracolorectal malignancies.
  • Basal and squamous cell carcinomas of the skin are not customarily included in the tumor spectrum of the syndrome.
  • PATIENT: The case of a 62-year old woman who had a history of colon cancer at the age of 46 years, endometrial cancer at the age of 56 years, baso-squamous, and squamous cell cancer of the face at the ages of 53, 54, 62 and 58 years, respectively, and rectal cancer at 60 is reported.
  • Her family fulfills the Amsterdam criteria for the diagnosis of hereditary nonpolyposis colorectal cancer.
  • The baso-squamous cell, the squamous cell, the endometrial and the rectal cancers were assessed for the microsatellite instability status and the expression of the MSH2 and MLH1 mismatch repair proteins, and the p53 tumor suppressor protein by immunohistochemistry.
  • The immunohistochemical staining in the baso-squamous cell, the squamous cell, the rectal and endometrial cancers were negative for MSH2 and positive for MLH1 proteins.
  • CONCLUSION: To the best of authors' knowledge, this is the first molecular characterization of a Hungarian hereditary nonpolyposis colorectal cancer family.
  • Cutaneous baso-squamous and squamous cell cancers may present as part of the HNPCC phenotype.
  • Detection of the loss of mismatch repair protein expression and mismatch repair gene mutation mapping, represents a significant improvement of the diagnosis of this syndrome in Hungary.
  • [MeSH-minor] Adaptor Proteins, Signal Transducing. Aged. Base Pair Mismatch. Carcinoma, Basal Cell / genetics. Carcinoma, Squamous Cell / genetics. Carrier Proteins. DNA Mutational Analysis. DNA Repair. DNA, Neoplasm / analysis. Decision Trees. Endometrial Neoplasms / genetics. Female. Genetic Testing. Humans. Hungary. Immunohistochemistry. Male. Microsatellite Repeats. Middle Aged. MutS Homolog 2 Protein. Pedigree

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15945244.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Carrier Proteins; 0 / DNA, Neoplasm; 0 / DNA-Binding Proteins; 0 / MLH1 protein, human; 0 / Neoplasm Proteins; 0 / Nuclear Proteins; 0 / Proto-Oncogene Proteins; EC 3.6.1.3 / MSH2 protein, human; EC 3.6.1.3 / MutS Homolog 2 Protein
  •  go-up   go-down


84. Yayli S, Akyazi H, Bahadir S, Alpay K, Cobanoğlu U: Coexistence of basal cell carcinomas and multiple sebaceous gland hyperplasias in a cyclosporine (ciclosporin)-treated renal transplant recipient. Am J Clin Dermatol; 2010;11(1):59-62
Hazardous Substances Data Bank. CYCLOSPORIN A .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Coexistence of basal cell carcinomas and multiple sebaceous gland hyperplasias in a cyclosporine (ciclosporin)-treated renal transplant recipient.
  • A 55-year-old man presented with multiple, asymptomatic, yellowish papules on his face with a 4-year history, and two non-healing tumoral lesions on his nose with a 7-month history.
  • A biopsy from the asymptomatic, yellowish papule on the face showed sebaceous gland hyperplasia, and biopsies from the lesions on the nose revealed basal cell carcinomas.
  • Sebaceous gland hyperplasia and skin cancers are among the cutaneous neoplasms observed in renal transplant recipients receiving cyclosporine.
  • To our knowledge, this is the third reported case of the coexistence of basal cell carcinomas and multiple sebaceous gland hyperplasias in a cyclosporine-treated renal transplant recipient.
  • [MeSH-major] Carcinoma, Basal Cell / chemically induced. Cyclosporine / adverse effects. Immunocompromised Host. Immunosuppressive Agents / adverse effects. Kidney Transplantation. Sebaceous Gland Diseases / chemically induced. Skin Neoplasms / chemically induced
  • [MeSH-minor] Face / pathology. Humans. Hyperplasia / chemically induced. Male. Middle Aged. Nose / pathology. Nose / surgery. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20000877.001).
  • [ISSN] 1175-0561
  • [Journal-full-title] American journal of clinical dermatology
  • [ISO-abbreviation] Am J Clin Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 83HN0GTJ6D / Cyclosporine
  •  go-up   go-down


85. Christensen E, Skogvoll E, Viset T, Warloe T, Sundstrøm S: Photodynamic therapy with 5-aminolaevulinic acid, dimethylsulfoxide and curettage in basal cell carcinoma: a 6-year clinical and histological follow-up. J Eur Acad Dermatol Venereol; 2009 Jan;23(1):58-66
Hazardous Substances Data Bank. DIMETHYL SULFOXIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy with 5-aminolaevulinic acid, dimethylsulfoxide and curettage in basal cell carcinoma: a 6-year clinical and histological follow-up.
  • OBJECTIVE: To investigate long-term clinical, histological and cosmetic follow-up results in basal cell carcinoma (BCC) after PDT, including treatment response related to patients and lesion characteristics.
  • Male sex and H-mid-face zone were significantly associated with recurrence.
  • [MeSH-major] Aminolevulinic Acid / therapeutic use. Carcinoma, Basal Cell / drug therapy. Dimethyl Sulfoxide / therapeutic use. Photochemotherapy. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18803580.001).
  • [ISSN] 1468-3083
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 88755TAZ87 / Aminolevulinic Acid; YOW8V9698H / Dimethyl Sulfoxide
  •  go-up   go-down


86. Lindemalm-Lundstam B, Dalenbäck J: Prospective follow-up after curettage-cryosurgery for scalp and face skin cancers. Br J Dermatol; 2009 Sep;161(3):568-76
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective follow-up after curettage-cryosurgery for scalp and face skin cancers.
  • BACKGROUND: Cryosurgery (CS) in the treatment of nonmelanoma skin cancers (NMSCs), especially in the face and on the scalp, has several advantages vs. other methods.
  • OBJECTIVES: To establish long-term results after curettage and CS (CCS) of NMSCs in the face and on the scalp considering complication rate, patient tolerance, cosmetic outcome and rate of recurrence.
  • METHODS: Seven hundred and twenty-six patients with 962 face and scalp NMSCs were prospectively followed after CCS (1 week, 3 months, and then annually) during the time period December 1994-September 2008.
  • CCS is thus a highly viable alternative in the treatment of NMSCs in the face and on the scalp.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Cryosurgery / methods. Head and Neck Neoplasms / surgery. Scalp. Skin Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19624544.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


87. Garnier B, Simon E, Dumont T, Sellal S, Stricker M, Chassagne JF: [Goal cell carcinoma: really a low malignancy tumor?]. Rev Stomatol Chir Maxillofac; 2005 Feb;106(1):16-21
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Goal cell carcinoma: really a low malignancy tumor?].
  • [Transliterated title] Les carcinomes cutanés basocellulaires méritent-ils leur réputation de tumeurs à faible malignité?
  • Although basal cell carcinoma often presents as a fairly "benign" lesion early in its course, it remains the most frequent malignancy worldwide.
  • We show that advanced basal cell carcinoma can be mutilating or even life threatening depending on location, type of lesion, or pre-existing co-morbidity.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Facial Neoplasms / pathology. Skin Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15798647.001).
  • [ISSN] 0035-1768
  • [Journal-full-title] Revue de stomatologie et de chirurgie maxillo-faciale
  • [ISO-abbreviation] Rev Stomatol Chir Maxillofac
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 22
  •  go-up   go-down


88. Santiago F, Serra D, Vieira R, Figueiredo A: Incidence and factors associated with recurrence after incomplete excision of basal cell carcinomas: a study of 90 cases. J Eur Acad Dermatol Venereol; 2010 Dec;24(12):1421-4
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence and factors associated with recurrence after incomplete excision of basal cell carcinomas: a study of 90 cases.
  • BACKGROUND: Management of incompletely excised basal cell carcinomas (BCC) remains controversial.
  • CONCLUSION: Observation might be an acceptable option in many situations, but for patients with aggressive types of BCC, or with tumours localized in risk areas of the face, immediate re-excision appears to be the treatment of choice.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Skin Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 The Authors. Journal compilation © 2010 European Academy of Dermatology and Venereology.
  • (PMID = 20384689.001).
  • [ISSN] 1468-3083
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


89. Emanuel PO, Rudikoff D, Phelps RG: Aggressive squamous cell carcinoma in Kindler syndrome. Skinmed; 2006 Nov-Dec;5(6):305-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aggressive squamous cell carcinoma in Kindler syndrome.
  • A 57-year-old Hispanic man with a personal and family history of bullae and photosensitivity presented with a fungating, ulcerated squamous cell carcinoma on his left hand (Figure 1).
  • There was reticulated erythema, atrophy, hyperpigmentation and hypopigmentation, and telangiectasia of sun-exposed skin of the face, neck, and hands consistent with poikiloderma (Figure 2).
  • Extensive histologic evaluation of the specimen obtained following left arm amputation and lymph node dissection showed moderate-to-poorly differentiated deeply invasive squamous cell carcinoma.
  • Two of 3 axillary lymph nodes were positive for metastatic carcinoma.
  • Electron microscopy illustrated extensive reduplication of the basement membrane, with loops, curls, and free extensions of the basal lamina in the superficial dermis; reduced numbers of hemidesmosomes and anchoring fibrils; and a basement membrane focally devoid of basal cells (Figure 4).
  • On the basis of the clinical features and the characteristic basement zone changes, a diagnosis of Kindler syndrome was made.
  • [MeSH-major] Carcinoma, Squamous Cell / diagnosis. Epidermolysis Bullosa / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Hand / pathology. Humans. Male. Middle Aged. Syndrome


90. Rybka MO, Cintra ML, de Souza EM, Metze K: Density of dendritic cells around basal cell carcinomas is related to tumor size, anatomical site and stromal characteristics, and might be responsible for the response to topical therapy. Int J Dermatol; 2008 Dec;47(12):1240-4
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Density of dendritic cells around basal cell carcinomas is related to tumor size, anatomical site and stromal characteristics, and might be responsible for the response to topical therapy.
  • BACKGROUND: The dermal dendritic cell (DC) is considered to be an important component of the host defense against basal cell carcinomas (BCCs).
  • RESULTS: In nonaggressive BBCs, a multiple linear regression showed that a higher DC density was associated with an increased number of myofibroblasts, smaller tumors and those located on the face.
  • For the aggressive subtypes, a higher DC density was related not only to an increased myofibroblast density, smaller BCCs or location on the face, but also to the presence of less mucinous and more granulation type stroma and an increased DC density in the normal dermis.
  • [MeSH-major] Adjuvants, Immunologic / administration & dosage. Aminoquinolines / administration & dosage. Antineoplastic Agents / administration & dosage. Carcinoma, Basal Cell / pathology. Langerhans Cells / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Administration, Topical. Adult. Aged. Aged, 80 and over. Cell Count. Facial Neoplasms / drug therapy. Facial Neoplasms / pathology. Female. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19126008.001).
  • [ISSN] 1365-4632
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Aminoquinolines; 0 / Antineoplastic Agents; 99011-02-6 / imiquimod
  •  go-up   go-down


91. Skroza N, Panetta C, Schwartz RA, Balzani A, Rota C, Buccheri EM, Alfano C, Innocenzi D: Giant meta-typical carcinoma: an unusual tumor. Acta Dermatovenerol Croat; 2006;14(1):46-51
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant meta-typical carcinoma: an unusual tumor.
  • Meta-typical carcinoma (MTC) or basosquamous carcinoma is a remarkable malignancy with features of both basal and squamous cell carcinoma.
  • It is typically located on the back and face, often with clinical features of basal cell carcinoma but tending to be more aggressive with enhanced prospects of lymph node or distant metastases.
  • Histologic examination of specimens from the margins and periphery revealed aspects of both basal and squamous cell carcinoma, while the ulcerated center showed sclerotic tissue without tumor.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Skin Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16603102.001).
  • [ISSN] 1330-027X
  • [Journal-full-title] Acta dermatovenerologica Croatica : ADC
  • [ISO-abbreviation] Acta Dermatovenerol Croat
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Croatia
  •  go-up   go-down


92. Tschen EH, Wong DS, Pariser DM, Dunlap FE, Houlihan A, Ferdon MB, Phase IV ALA-PDT Actinic Keratosis Study Group: Photodynamic therapy using aminolaevulinic acid for patients with nonhyperkeratotic actinic keratoses of the face and scalp: phase IV multicentre clinical trial with 12-month follow up. Br J Dermatol; 2006 Dec;155(6):1262-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy using aminolaevulinic acid for patients with nonhyperkeratotic actinic keratoses of the face and scalp: phase IV multicentre clinical trial with 12-month follow up.
  • AKs are believed to progress to in situ squamous cell carcinoma (SCC) and potentially, to invasive SCC.
  • (iii) to characterize the histopathology of untreated clinically diagnosed AK lesions in the study population at baseline; and (iv) to evaluate ALA-PDT in darker skin types than previously studied.
  • METHODS: Patients enrolled in this study had six to 12 discrete AK lesions, either on the face or the scalp.
  • With respect to the lesions biopsied, 91% (127/139) were diagnosed histopathologically as AK, with the balance of lesions being SCC (nine of 139: 7%), basal cell carcinoma (one of 139: 0.7%) and other non-AK diagnoses (two of 139: 1%).
  • The clinical diagnosis of AK by investigators appeared to be accurate, with 91% (200/220) of the untreated clinically diagnosed AK lesions being histopathologically confirmed to be AK (AK, 142/220: 65%; advanced AK, 29/220: 13%; macular AK, 29/220: 13%).
  • Despite concentrated efforts to recruit patients with Fitzpatrick skin types IV-VI, the distribution was as follows: I, 11%; II, 36%; III, 41%; IV, 11%; V, 2%.
  • CONCLUSIONS: ALA-PDT was shown to be an effective and safe therapy for the treatment of AKs of the face and scalp in skin types I-V, with an acceptable rate of recurrence over 12 months of histologically confirmed AKs of 19%.
  • Phototoxicity reactions were all expected, nonserious and had essentially resolved after 1 month post-treatment independent of skin type.

  • MedlinePlus Health Information. consumer health - Dandruff, Cradle Cap, and Other Scalp Conditions.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17107399.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase IV; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


93. Goldberg LH, Kimyai-Asadi A: Diffuse epidermal and periadnexal squamous cell carcinoma in situ: a report of 13 patients. J Am Acad Dermatol; 2005 Oct;53(4):623-7
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffuse epidermal and periadnexal squamous cell carcinoma in situ: a report of 13 patients.
  • BACKGROUND: Diffuse epidermal and periadnexal squamous cell carcinoma in situ (DEPS) is a condition in which large areas of skin are affected by atypical keratinocytes that grow beneath the epidermis and encase adnexal epithelia.
  • The lesions were present on the scalp, face, and neck.
  • In the 52 cumulative patient-years of follow-up, we treated 80 invasive squamous cell and 48 basal cell carcinomas in these patients.
  • CONCLUSION: DEPS is characterized by diffuse involvement of chronically sun-exposed skin with atypical keratinocytes that grow along the inferior portion of the basal layer of the epidermis and around adnexal structures.
  • DEPS is also associated with the development of invasive squamous cell and basal cell carcinomas.
  • [MeSH-major] Carcinoma in Situ / pathology. Carcinoma, Squamous Cell / pathology. Epidermis / pathology. Facial Neoplasms / pathology. Keratinocytes / pathology. Skin Neoplasms / pathology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16198782.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


94. Apalla Z, Sotiriou E, Chovarda E, Lefaki I, Devliotou-Panagiotidou D, Ioannides D: Skin cancer: preventive photodynamic therapy in patients with face and scalp cancerization. A randomized placebo-controlled study. Br J Dermatol; 2010 Jan;162(1):171-5
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Skin cancer: preventive photodynamic therapy in patients with face and scalp cancerization. A randomized placebo-controlled study.
  • Background Patients with a previous medical history of nonmelanoma skin cancers (NMSCs) often develop multiple or recurrent malignant lesions around the site of the primary tumour.
  • This finding led to the field cancerization theory, which suggests that the entire epithelial surface of the regional skin has an increased risk for the development of malignant lesions.
  • Objectives We sought to investigate whether field-photodynamic therapy (PDT) of extreme photodamaged skin would prevent new NMSCs, in comparison with a control area receiving placebo-PDT, in patients with clinical and histological signs of field cancerization.
  • Methods Forty-five patients, previously diagnosed as having NMSCs of the face or scalp, with actinic keratoses symmetrically distributed over the same regions, were randomized for field treatment with 20% aminolaevulinic acid (ALA)-PDT on one side and placebo-PDT on the other.
  • [MeSH-major] Facial Neoplasms / prevention & control. Head and Neck Neoplasms / drug therapy. Neoplasms, Second Primary / prevention & control. Photochemotherapy. Scalp. Skin Neoplasms / prevention & control
  • [MeSH-minor] Aged. Aged, 80 and over. Aminolevulinic Acid / therapeutic use. Carcinoma, Basal Cell / drug therapy. Carcinoma, Squamous Cell / drug therapy. Female. Humans. Keratosis, Actinic / drug therapy. Male. Middle Aged. Photosensitizing Agents / therapeutic use

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19863513.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


95. Sun J, Gui X, He J, Liu HM, Yu HY, Xia CY, Xu Y: [The relationship between infestation of Demodex folliculorum and epidermal neoplasm on face]. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi; 2005 Dec 30;23(6):428-31
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The relationship between infestation of Demodex folliculorum and epidermal neoplasm on face].
  • METHODS: A retrospective analysis was made with the pathological data of 153 cases collected in the recent four years on facial basal cell carcinoma, squamous cell carcinoma, seborrheic keratosis and trichilemmoma.
  • RESULTS: There was a significant difference in the infestation rate of Demodex folliculorum in the four types of epidermal neoplasm(P < 0.05), with the highest rate in basal cell carcinoma(56%), compared with seborrheic keratosis (21%), trichilemmoma (20%), and squamous cell carcinoma (14%).
  • In addition, among twelve cases of Demodex folliculorum positive nasal neoplasm, nine were basal cell carcinoma; ten of thirty-six basal cell carcinoma occurred on nose.
  • CONCLUSION: The highest infestation rate of Demodex folliculorum was in cases of nasal epidermal neoplasm compared with other locations, and the cases of basal cell carcinoma showed the highest infestation rate among the four types of neoplasm.
  • [MeSH-major] Facial Neoplasms / etiology. Mite Infestations / complications. Skin Neoplasms / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16566213.001).
  • [ISSN] 1000-7423
  • [Journal-full-title] Zhongguo ji sheng chong xue yu ji sheng chong bing za zhi = Chinese journal of parasitology & parasitic diseases
  • [ISO-abbreviation] Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


96. Rio E, Bardet E, Ferron C, Peuvrel P, Supiot S, Campion L, De Montreuil CB, Mahe MA, Dreno B: Interstitial brachytherapy of periorificial skin carcinomas of the face: a retrospective study of 97 cases. Int J Radiat Oncol Biol Phys; 2005 Nov 1;63(3):753-7
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interstitial brachytherapy of periorificial skin carcinomas of the face: a retrospective study of 97 cases.
  • PURPOSE: To analyze outcomes after interstitial brachytherapy of facial periorificial skin carcinomas.
  • PATIENTS AND METHODS: We performed a retrospective analysis of 97 skin carcinomas (88 basal cell carcinomas, 9 squamous cell carcinomas) of the nose, periorbital areas, and ears from 40 previously untreated patients (Group 1) and 57 patients who had undergone surgery (Group 2).
  • We calculated survival rates and assessed functional and cosmetic results de visu.
  • CONCLUSIONS: Brachytherapy provided a high level of local control and good cosmetic results for facial periorificial skin carcinomas that pose problems of surgical reconstruction.
  • [MeSH-major] Brachytherapy / methods. Carcinoma, Basal Cell / radiotherapy. Carcinoma, Squamous Cell / radiotherapy. Facial Neoplasms / radiotherapy. Skin Neoplasms / radiotherapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15927410.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Iridium Radioisotopes
  •  go-up   go-down


97. Gabillot-Carré M, Weill F, Mamelle G, Kolb F, Boitier F, Petrow P, Ortoli JC, Margulis A, Souteyrand P, Mercier S, Spatz A, Duvillard P, Validire P, Avril MF: Microcystic adnexal carcinoma: report of seven cases including one with lung metastasis. Dermatology; 2006;212(3):221-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microcystic adnexal carcinoma: report of seven cases including one with lung metastasis.
  • BACKGROUND: Microcystic adnexal carcinoma (MAC) is a rare cutaneous neoplasm, with a high rate of local recurrences.
  • RESULTS: The primary MAC were located on the face in all patients, and 85% were initially misdiagnosed.
  • [MeSH-major] Carcinoma, Skin Appendage / pathology. Facial Neoplasms / pathology. Lung Neoplasms / secondary. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Carcinoma, Basal Cell / diagnosis. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local

  • Genetic Alliance. consumer health - Microcystic adnexal carcinoma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2006 S. Karger AG, Basel
  • (PMID = 16549917.001).
  • [ISSN] 1018-8665
  • [Journal-full-title] Dermatology (Basel, Switzerland)
  • [ISO-abbreviation] Dermatology (Basel)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


98. Zamanian A, Farshchian M, Meheralian A: A 10-year study of squamous cell carcinoma in Hamedan in the west of Iran (1993-2002). Int J Dermatol; 2006 Jan;45(1):37-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A 10-year study of squamous cell carcinoma in Hamedan in the west of Iran (1993-2002).
  • BACKGROUND: Cutaneous squamous cell carcinoma (SCC) is the second most common form of skin cancer in Caucasians.
  • RESULTS: From a total of 6846 biopsies, 669 skin cancers were diagnosed, including 449 (66.67%) basal cell carcinomas (BCC) and 179 (26.76%) SCC.
  • The head and face were the most common sites of SCC location.
  • CONCLUSION: SCC is the second most common form of skin malignancy in the west of Iran.
  • [MeSH-major] Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / pathology. Skin Neoplasms / epidemiology. Skin Neoplasms / pathology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16426373.001).
  • [ISSN] 0011-9059
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


99. Dore DD, Lapane KL, Trivedi AN, Mor V, Weinstock MA: Association between statin use and risk for keratinocyte carcinoma in the veterans affairs topical tretinoin chemoprevention trial. Ann Intern Med; 2009 Jan 6;150(1):9-18
Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association between statin use and risk for keratinocyte carcinoma in the veterans affairs topical tretinoin chemoprevention trial.
  • BACKGROUND: Recent evidence suggests that statins may prevent cancer.
  • OBJECTIVE: To quantify the association between statin use and the occurrence of keratinocyte carcinoma in high-risk veterans.
  • PARTICIPANTS: 1037 participants of the Veterans Affairs Topical Tretinoin Chemoprevention Trial, a randomized, multicenter, double-blind, vehicle-controlled trial of topical tretinoin, 0.1%, for prevention of keratinocyte carcinoma conducted from November 1998 to November 2004.
  • MEASUREMENTS: Time to first occurrence of keratinocyte carcinoma on the face or ears.
  • In the propensity score-matched analysis, statin use at randomization was not associated with keratinocyte carcinoma (rate ratio, 0.92 [95% CI, 0.73 to 1.16]), a finding that was consistent with the estimates derived from the Cox proportional hazards regression (rate ratio, 0.84 [CI, 0.70 to 1.02]).
  • CONCLUSION: These data show no conclusive or consistent relationship between long-term statin use and risk for keratinocyte carcinoma.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] JAMA. 2006 Jun 21;295(23):2721; author reply 2721-2 [16788124.001]
  • [Cites] N Engl J Med. 2006 Aug 10;355(6):549-59 [16899775.001]
  • [Cites] Int J Clin Pract. 2006 Sep;60(9):1028-34 [16939542.001]
  • [Cites] Am J Cardiol. 2006 Oct 1;98(7):923-8 [16996875.001]
  • [Cites] J Natl Cancer Inst. 2006 Dec 20;98(24):1819-25 [17179483.001]
  • [Cites] Circulation. 2007 Jan 2;115(1):27-33 [17179016.001]
  • [Cites] J Natl Cancer Inst. 2007 Jan 3;99(1):32-40 [17202111.001]
  • [Cites] Epidemiology. 2007 Mar;18(2):213-9 [17235211.001]
  • [Cites] Dement Geriatr Cogn Disord. 2007;23(3):194-201 [17259710.001]
  • [Cites] J Am Acad Dermatol. 2007 Aug;57(2):279-84 [17482716.001]
  • [Cites] Gastroenterology. 2007 Aug;133(2):393-402 [17681160.001]
  • [Cites] J Invest Dermatol. 2007 Oct;127(10):2323-7 [17522705.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Nov;16(11):2218-25 [17971519.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Nov;16(11):2226-32 [18006910.001]
  • [Cites] J Natl Cancer Inst. 2008 Jan 16;100(2):134-9 [18182618.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Jan;17(1):88-94 [18199714.001]
  • [Cites] Urology. 2008 Jan;71(1):118-22 [18242378.001]
  • [Cites] Am J Med. 2008 Apr;121(4):302-9 [18374689.001]
  • [Cites] Am J Gastroenterol. 2008 Apr;103(4):825-37 [18371146.001]
  • [Cites] Cancer Causes Control. 2008 Sep;19(7):767-74 [18322813.001]
  • [Cites] JAMA. 2000 Jun 28;283(24):3211-6 [10866868.001]
  • [Cites] Arch Intern Med. 2000 Aug 14-28;160(15):2363-8 [10927735.001]
  • [Cites] Arch Dermatol. 2001 Aug;137(8):1055-8 [11493098.001]
  • [Cites] Med Care. 2003 Jun;41(6):761-74 [12773842.001]
  • [Cites] Pharmacotherapy. 2003 Jun;23(6):726-30 [12820814.001]
  • [Cites] Arch Intern Med. 2004 Jan 26;164(2):146-52 [14744837.001]
  • [Cites] Med Care Res Rev. 2003 Sep;60(3 Suppl):92S-123S [15095548.001]
  • [Cites] Am J Cardiol. 2004 May 1;93(9):1124-9 [15110204.001]
  • [Cites] Lancet. 2004 May 15;363(9421):1607-8 [15145635.001]
  • [Cites] Lancet Neurol. 2004 Jun;3(6):369-71 [15157852.001]
  • [Cites] Arch Dermatol. 2004 Sep;140(9):1079-85 [15381547.001]
  • [Cites] J Chronic Dis. 1987;40(5):373-83 [3558716.001]
  • [Cites] Arch Dermatol. 1991 Aug;127(8):1194-7 [1863078.001]
  • [Cites] J Clin Epidemiol. 1993 Oct;46(10):1075-9; discussion 1081-90 [8410092.001]
  • [Cites] Arch Dermatol. 1993 Oct;129(10):1286-90 [8215493.001]
  • [Cites] J Am Acad Dermatol. 1994 May;30(5 Pt 1):774-8 [8176018.001]
  • [Cites] Int J Cancer. 1995 Feb 8;60(4):489-94 [7829262.001]
  • [Cites] Arch Dermatol. 1995 Feb;131(2):164-9 [7857112.001]
  • [Cites] J R Soc Med. 1997 Jul;90(7):371-4 [9290417.001]
  • [Cites] JAMA. 1998 May 27;279(20):1615-22 [9613910.001]
  • [Cites] Lancet. 1999 Aug 28;354(9180):723-9 [10475183.001]
  • [Cites] Int J Cancer. 2005 Apr 20;114(4):643-7 [15578694.001]
  • [Cites] N Engl J Med. 2005 Apr 7;352(14):1425-35 [15755765.001]
  • [Cites] N Engl J Med. 2005 May 26;352(21):2184-92 [15917383.001]
  • [Cites] Pharmacoepidemiol Drug Saf. 2005 Jul;14(7):465-76 [15651087.001]
  • [Cites] Cochrane Database Syst Rev. 2005;(4):CD003697 [16235336.001]
  • [Cites] JAMA. 2005 Nov 16;294(19):2437-45 [16287954.001]
  • [Cites] Curr Cancer Drug Targets. 2005 Dec;5(8):579-94 [16375664.001]
  • [Cites] JAMA. 2006 Jan 4;295(1):74-80 [16391219.001]
  • [Cites] Oncologist. 2006 Mar;11(3):306-15 [16549815.001]
  • [Cites] Int J Cancer. 2006 Aug 1;119(3):682-6 [16496410.001]
  • [Cites] Am J Epidemiol. 2006 Jun 15;163(12):1149-56 [16624967.001]
  • [Cites] JAMA. 2006 Jun 21;295(23):2720-1; author reply 2721-2 [16788122.001]
  • (PMID = 19124815.001).
  • [ISSN] 1539-3704
  • [Journal-full-title] Annals of internal medicine
  • [ISO-abbreviation] Ann. Intern. Med.
  • [Language] ENG
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00007631
  • [Grant] United States / NCI NIH HHS / CA / R01 CA106592; United States / NCI NIH HHS / CA / R25CA087972; United States / NCI NIH HHS / CA / R01CA106807; United States / NIAMS NIH HHS / AR / R01 AR049342; United States / AHRQ HHS / HS / 5T32HS000011-21; United States / NCI NIH HHS / CA / R01 CA106807; United States / NCI NIH HHS / CA / R25 CA087972; United States / NCI NIH HHS / CA / R01CA106592; United States / AHRQ HHS / HS / T32 HS000011; United States / NIAMS NIH HHS / AR / R01AR49342
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 5688UTC01R / Tretinoin
  • [Other-IDs] NLM/ NIHMS507348; NLM/ PMC3771656
  •  go-up   go-down


100. Kokcam I, Saki CE: A case of cutaneous myiasis caused by Wohlfahrtia magnifica. J Dermatol; 2005 Jun;32(6):459-63
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 46-year-old male farmer with nevoid basal cell carcinoma syndrome (NBCCS) presented with the complaint of a blood-tinged discharge and pain in the left frontal-temporal region for three days.
  • Physical examination revealed live maggots in the ulcerous wound resulting from basal cell carcinoma.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Diptera / parasitology. Myiasis / diagnosis. Skin Diseases, Parasitic / diagnosis. Skin Neoplasms / pathology
  • [MeSH-minor] Agriculture. Animals. Face. Follow-Up Studies. Humans. Larva. Male. Middle Aged. Risk Assessment. Scalp. Treatment Outcome. Turkey

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16043920.001).
  • [ISSN] 0385-2407
  • [Journal-full-title] The Journal of dermatology
  • [ISO-abbreviation] J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 22
  •  go-up   go-down






Advertisement